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ABSTRACT
SPECTRAL CHARACTERIZATION OF CYTOCHROMES P450 ACTIVE SITES
AND CATALYTIC INTERMEDIATES
Daniel Kaluka, B.Sc., M.S.
Marquette University, 2012
Cytochromes P450 (P450s) have been the subject of intense research for over six
decades. Though it is widely accepted that a highly reactive Fe(IV)=O π-cation radical, or
the so called compound I, facilitates the oxidation of relatively inert hydrocarbons,
spectroscopic characterization of this putative intermediate has eluded detection under
turnover conditions, presumably due to its very short lifetime. In this work, chemically
inert substrates of P450s have been utilized in a new approach to capture and stabilize
this transient intermediate and characterize it with resonance Raman (RR) spectroscopy,
which is a well established tool for studying heme proteins. Specifically,
perfluorodecanoic acid has been utilized as an inert surrogate substrate of a thermophilic
cytochrome P450 designated CYP119 and RR and cryoradiolysis methods were
employed to characterize the enzymatic intermediates under turnover conditions.
In a separate project, a recent and more efficient approach for the isotopic labeling
of the prosthetic group in heme proteins has been exploited to produce a 13C labeled
analogue of the soluble bacterial cytochrome P450cam (P450cam). Briefly, the HU227
strain of E. coli that lacks the δ-aminolevulinic acid (δ-ALA) synthase gene was
employed in the heterologous expression of P450cam harboring a prosthetic group
labeled with 13C at the Cm and Cα positions by growing cells in the presence of [5-13C] δALA, which was synthesized in four steps from [2-13C] glycine. This system has been
utilized as proof of principle for the strategy of defining active site structure in
mammalian cytochromes P450 using NMR methods to furnish necessary experimental
restrictions in docking routines, which are commonly employed in determining the
relative affinities of drug candidates. Noting that few crystal structures of substrate bound
complexes of drug metabolizing P450s exist, a truncated CYP2D6 gene has been
designed following a recently published procedure and efforts were made to
heterologously express a selectively 13C enriched analogue of this important drug
metabolizing enzyme.
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CHAPTER 1 GENERAL INTRODUCTION
1.1 Cytochromes P450
Klingenberg (1958) is credited for the identification of the first cytochrome P450
in rat liver michrosomes.1 A little later, in the early 1960s, Omura and Sato observed a
characteristic Soret absorption maximum around 450 nm in the UV spectrum (Figure
1.1.1) of a carbon monoxide saturated liver microsomes sample incubated with sodium
diothionite2 These observations led to wide-ranging exploration of a class of heme
proteins known as cytochromes P450 (P450s).

Figure 1.1.1 The Fe (II)-CO difference spectra of liver michrosomes. A, Na2S2O4
reduced microsomes; B, aerobic microsomes.2

These single polypeptide chain heme proteins of between 400-500 amino acid
residues are found in all five biological kingdoms.3,4 The name heme proteins is derived
from the characteristic iron-porphyrin prosthetic group or the so-called heme, in the

2
active site of these proteins. Natural occurring heme types include heme a, b, c and d
(Figure 1.1.2)5,6 Heme b bearing proteins have been the subject of intensive structure
function studies. The prosthetic group’s attachment to the surrounding protein matrix
accounts for the apparent versatility and ubiquitous nature of these metalloproteins.7 The
heme group in P450s is covalently linked to the protein via an Fe‒S bond (provided by a
cysteinic sulfur acting as the fifth ligand) bond at the proximal side of the prosthetic
group, whereas most other heme proteins such as, hemoglobin and myoglobin exhibit a
histidyl imidazole linkage.8,9Additional covalent attachments with the heme peripheral
groups have been documented for lactoperoxidases and myeloperoxidases.10,11

3

Figure 1.1.2 The structures (and numbering) of the natural occurring heme groups (ad)5,6
The heightened research focus on this class of heme proteins stems primarily from
their role as biological catalysts. P450s have been reported to bind and cleave molecular
oxygen generating a potent intermediate capable of hydroxylating even relatively inert
hydrocarbon substrates.12,13This interesting chemistry has been observed in a variety of
important biological processes that include biosynthesis of lipids, steroids, antibiotics and
the degradation of xenobiotics (Figure 1.1.3).7 It is obviously of immense practical
interest to gain a better understanding of this apparently ubiquitous chemistry exhibited
by these important biological catalysts.

4

Figure 1.1.3 The many roles of P450cam in metabolism7

1.1.1 The P450s catalytic cycle

The advancement in genomic studies has seen the unraveling of greater than 3000
genes encoding P450s in plant, fungi, bacterial and mammalian sources.3,4 Among these,
a soluble heme protein known as cytochrome P450cam (P450cam) from the bacteria
Pseudomonas putida has been well studied. 14–16 Researchers attempting to better
understand the chemistry of P450s have taken advantage of this probably best
characterized prototype of the P450 superfamily. Crystal structure studies have detected
the presence of a hydrogen bonded water cluster in the substrate-free enzyme’s distal

5
pocket.15,17–19 In the resting state, one of the water molecules is bound to the ironporphyrin complex giving a hexa-coordinated low spin ferric form of the enzyme (Figure
1.1.4).20 It has now been well documented that binding of camphor (or its analogues) or
redox partners by P450cam induce structural changes with important functional
significance.21,22 In the catalytic cycle shown in Figure 1.1.4, binding of substrate to a
relatively planar hexa-coordinated iron-porphyrin complex induces a spin state change to
a 5-coordinate high spin (5CHS) form of the enzyme (2). In P450cam, it has been shown
that binding of substrate and its redox partner, putidaredoxin, modulates the heme
equilibrium redox potential (from -303 mV to -173 mV) signifying susceptibility to
reduction of the 5CHS P450cam (Figure 1.1.5).21,23–25 Delivery of one electron
equivalent, by putidaredoxin, is followed by binding of oxygen, giving rise to a dioxygen
adduct of P450cam (4). Spectroscopic characterization of this intermediate in P450cam is
well documented.26–29 Addition of a second electron by the redox partner produces the
heme-bound peroxo intermediate (5a). This intermediate (5a) and its protonated form, the
ferric hydroperoxo species (5b) have recently been characterized by electronic
absorption, EPR and resonance Raman spectroscopic methods.20,28,30 Proton assisted
scission of the dioxygen bond of the hydroperoxo species results in the formation of the
transient reactive intermediate of P450s (6), the equivalent of the so-called compound I of
peroxidases. This elusive intermediate has eluded spectroscopic characterization under
turnover conditions.

6

Figure 1.1.4 The catalytic cycle of P450cam20

7

Figure 1.1.5 The structures of all the three components of P450cam23

1.1.2 Heme iron interactions with diatomic ligands
Important structural data have been obtained by taking advantage of the fact that
these heme proteins are capable of binding exogenous diatomic ligands such as NO, CO
and CN- in addition to the endogenous O2 discussed above for P450cam. The binding of
these ligands to the iron-porphyrin complex through σ- and π-interactions gives rise to
linear or bent geometries (Figure 1.1.6).31–33 The dispositions of these ligands in the
active site, which can be spectroscopically interrogated, have been used as probes
reporting on active site architecture that can influence important functional properties of
heme proteins. Two σ type interactions are possible: one in which the metal dz2 orbital
overlaps with the ligand lone pair and another involving the metal dz2 and the ligand π*
orbitals. The strength of the metal-ligand bond depends on the extent of orbital overlap,
thus weak bonding exists between metal and a ligand exhibiting a high energy π* orbital.

8
For example, the strength of σ-bonding interaction increases from CO, NO to O2 as the
π*-orbital energy decreases. In π-interactions, back donation of electrons from the filled
metal dxy and dyz orbitals to the vacant ligand π* orbital results in the strengthening of the
M-X bond and weakening of the X-Y bond. Although the nature of these interactions
defines the theoretical geometry of the M-X-Y linkage, distortions are to be expected in
the protein matrix due to the interactions between the ligand and amino acid residues in
close proximity.6

Figure 1.1.6 Schematic representation of σ- and π-bonding in heme proteins.8
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1.1.3 Optical properties of cytochromes P450
The optical properties exhibited by cytochromes P450 enzymes allows for the use
of a variety of spectroscopic tools in the quest for an understanding of the inherent
chemistry observed in these proteins. The heme group in P450s gives rise to strong π-π*
electronic transitions in the visible region due to the extended nature of the porphyrin
aromatic system. The spectral features of a typical metalloporphyrin, ferrocytochrome c,
are shown in the figure below (Figure 1.1.7).6 The characteristic bands include an intense
band at around 400 nm, the so-called B or Soret band and a pair of weak bands near 520
nm and 550 nm, referred to as Q0(or α) and Q1(or β) bands, respectively. The
unsubstituted tetrapyrrole macrocycle has D4h symmetry exhibiting two degenerate
lowest unoccupied π* orbitals (LUMO) of eg symmetry and two highest filled π orbitals
(HOMO) of a1g and a2u symmetries. The energies of the two HOMOs are nearly the same
allowing strong configuration interaction of the possible transitions, A1u  Eg and A2u 
Eg; addition of the transition dipoles gives rise to the strong Soret band whereas they
nearly cancel out for the Q0 transition. The apparent increase in intensity observed for the
Q1 transition is a result of vibronic mixing with the B transition.6,34
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Figure 1.1.7 Absorption spectrum of Cytochrome c and the structure of a
metalloporphyrin with D4h symmetry6

The 6 coordinate low spin (6CLS) substrate-free P450cam exhibits a Soret
absorption maximum at 418 nm, which shifts down to 391 nm upon binding of substrate.
The downshift is associated with spin state change from the 6CLS to 5CHS (Figure
1.1.8).35 Cytochrome P420cam, the inactive form of P450cam, has a Soret band at 420
nm, which is presumably the reduced carbonmonoxy form (reduced P420-CO form)
exhibiting histidyl ligation. The proximal thiolate fifth ligand is thought to be replaced by
a histidyl residue resulting in a lack of enzymatic activity giving evidence of the critical
role played by the axial ligand in heterolytic cleavage of the dioxygen species trans to
it.36 However, later studies have suggested that the P420 form may be reasonably
described as possessing a protonated thiol axial ligand.37
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Figure 1.1.8 Absorption spectra of different forms of P450cam in the Soret region;
Fe(III) substrate free (mo), Fe(III) substrate bound (mos), Fe(II) substrate bound (mrs),
Fe(II)-CO substrate bound
).35
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1.2 Raman Spectroscopy
The Raman Effect phenomenon results when light from a laser source impinges
upon a molecule and interacts with the electron cloud of the bonds making up the
molecule. Interaction with the incident radiation may result in vibrational excitation of
the molecule from its electronic ground state, ν0 and/or a less populated vibrational
excited state, ν1 to a virtual energy state. Stokes Raman scattering, or the so-called
spontaneous Raman Effect, is generated following vibrational relaxation whereby the
energy of the scattered light is less than the incident radiation. Vibrational relaxation
from a virtual excited to the electronic ground state (ν0) results in Rayleigh or elastic
scattering; that is, the energy of the incident photon is the same as that of the emitted
photon. Excitation of the molecule already in a vibrational excited state (ν1) followed by
relaxation to a lower vibrational level (ν0) produces anti-Stokes Raman scattering, as
shown in the figure below (Figure 1.2.1). As expected and in accordance with the
Maxwell-Boltzmann distribution law, Stokes Raman scattering exhibits stronger
intensities than anti-Stokes since the vibrational excited levels (ν1) are far much less
populated than the ground state (ν0); i.e., the intensities of the anti-Stokes Raman lines
decreases rapidly as the vibrational frequencies increase. Consequently, conventional
Raman spectroscopy considers the Stokes lines in which the scattered light intensities are
reported as a function of the frequency difference from the monochromatic source or
more commonly as Raman shifts. Key to the exhibition of the Raman Effect is the
polarizability of the molecule with respect to the vibrational coordinate. The degree of
polarizability is reflected in the Raman scattering intensity, whereas Raman shifts report
on the molecular vibrational levels.
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Figure 1.2.1 Schematic representation of the Raman Effect
1.2.1 Resonance Raman Spectroscopy

Resonance Raman spectroscopy involves measuring enhanced Stokes lines as the
excitation frequency approaches the energy of the electronic transition of the target
chromophore. The technique is ideally suited for studying complex biological molecules
like heme proteins inasmuch as it permits active site interrogation owing to its ability to
selectively enhance vibrational modes of the chromophoric heme prosthetic group.38 This
powerful spectroscopic tool has long been established as an exquisite probe of active site
structure for a wide range of heme proteins and enzymes.6,38,39 The technique offers a
major advantage over IR spectroscopy in that there is no interference from water making
it a method of choice for studying vibrational properties of proteins, samples of which are
typically in aqueous buffers. The vibrational modes of the prosthetic heme group buried
in the active site of these large biological polymers are selectively enhanced by exploiting
laser (excitation) lines which are in or near resonance with the Soret or Q bands
electronic transitions.
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Isotopic labeling (15N, 13C and 2H) of high symmetry model compounds, such as
metal complexes of tetraphenylporphyrin (H2TPP), octaethylporphyrin (H2OEP),
etioporphyrins (H2(EtioI)) and (H2(EtioIII), has been used to unambiguously assign heme
core vibrational modes.40,41 If each peripheral substituent of the iron protopophyrin IX
complex is considered as a point mass, the heme has D4h symmetry giving a total of 37
atoms and 105 vibrational modes. The modes consist of 71 in-plane (ip) modes (2N-3)
and 34 out-of-plane (oop) modes (N-3) and are classified as follows:
ip = 9A1g + 8A2g + 9B1g + 9B2g + 18Eu
oop =3A1u + 6A2u + 5B1u + 4B2u + 8Eg
Of the 71 in-plane vibrational modes 35 (g symmetry) are Raman active whereas 18 (Eu)
are infrared active. These modes have been assigned for Ni2+ complexes of OEP,
porphine and TPP using isotopic substitution and normal coordinate analysis and are
given in the table below (Table 1.2.1).6,42–45
Most applications have focused on the so-called marker bands in the high
frequency region, which effectively document oxidation and spin states of the central
iron, in addition to providing a reliable indicator of heme core size.6,40 The oxidation
marker band (4), occurring at ~1360 cm-1 in Fe(II) and ~1375 cm-1 in Fe(III) species, is
ascribable to the pyrrole ring symmetric stretch, which is very sensitive to the oxidation
state of the central iron. The so-called spin state marker bands (ν2, ν3 and ν10) report on
the core size and spin state of the iron center (Table 1.2.1). In recent years it has become
increasingly apparent that low frequency modes (100-600 cm-1) in the RR spectra of
heme proteins are quite sensitive to active site structure changes that can induce out-of-
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plane distortions of the macrocycle or alter the orientation of the heme peripheral
substituents46–55 (see Figure 1.1.1 for protoheme labeling scheme).
Table 1.2.1 Assignment and frequencies of in-plane vibrational modes of some nickel
porphyrins complexes6

Symmetry
A 1g

B1g

A 2g

B2g

Eu

νi
ν1
ν2
ν3
ν4
ν5
ν6
ν7
ν8
ν9
ν10
ν11
ν12
ν13
ν14
ν15
ν16
ν17
ν18
ν19
ν20
ν21
ν22
ν23
ν24
ν25
ν26
ν27
ν28
ν29
ν30
ν31
ν32
ν33
ν34
ν35
ν36
ν37
ν38
ν39
ν40
ν41
ν42
ν43
ν44
ν45
ν46
ν47
ν48
ν49
ν50
ν51
ν52
ν53

Description
ν(Cm-X)
ν(CβCβ)
ν(Cα-Cm)sym
ν(Pyr half ring)sym
ν(Cβ-Y)sym
ν(Pyr breathing)
δ(Pyr def)sym
ν(Ni-N)
δ(Cβ-Y)sym
ν(Cα-Cm)asym
ν(CβCβ)
ν(Pyr half ring)sym
δ(Cm-X)
ν(Cβ-Y)sym
ν(Pyr breathing)
δ(Pyr def)sym
δ(Cb-Y)sym
ν(Ni-N)
ν(Cα-Cm)asym
ν(Pyr quarter ring)
δ(Cm-X)
ν(Pyr half ring)asym
ν(Cβ-Y)asym
δ(Pyr def)asym
δ(Pyr rot.)
δ(Cβ-Y)asym
ν(Cm-X)
ν(Cα-Cm)sym
ν(Pyr quarter ring
ν(Pyr half ring)asym
ν(Cβ-Y)asym
δ(Pyr def)asym
δ(Pyr rot.)
δ(Cβ-Y)asym
δ(Pyr tranl.)
ν(Cm-X)
ν(Cα-Cm)asym
ν(CβCβ)
ν(Cα-Cm)sym
ν(Pyr quarter ring)
ν(Pyr half ring)sym
δ(Cm-X)
ν(Cβ-Y)sym
ν(Pyr half ring)asym
ν(Cβ-Y)asym
δ(Pyr)asym
ν(Pyr breathing)
δ(Pyr)sym
δ(Pyr rot.)
ν(Ni-N)
δ(Cb-Y)asym
δ(Cβ-Y)sym
δ(Pyr transl)

NiOEP
[3041]
1602
1520
1383
1138
804
674
360/343
263/274
1655
1577
1331
1220
1131
751
746
305
168
1603
1394
1307
1121
1058
597
551
[243]
[3041]
1483
1407
1160
1015
938
493
197
144
[3040]
[1637]
1604
1501
1396
[1346]
1231
1153
1133
996
927
766
605
544
[358]
328
263
212

NiP
[3042]
1575
1459
1376
[3097]
995
731
369
1066
1650
1505
1319
1185
[3097]
1003
730
1060
237
1611
1354
1139
1005
[3087]
806
429
1317
[3041]
1504
1368
1003
[3088]
819
435
1193
197
[3042]
1624
1547
1462
1385
1319
1150
[3097]
1033
[3087]
806
995
745
366
420
1064
1250
282

NiTPP
1235
1572
1470
1374
[3097]
1004
889
402
1079
1594
1504
1302
238
[3097]
1009
846
784
277
1550
1341
[257]
1016
[3087]
828
560
1230
1269
[1481]
1377
1004
[3087]
869
450
1191
109
[1254]
[1586]
[1552]
[1473]
[1403]
[1331]
[233]
[3097]
[1003]
[3100]
[864]
[1023]
[895]
[512]
[436]
[1093]
[1213]
[306]
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1.2.2 RR spectroscopy of cytochromes P450
RR spectroscopy has unraveled a wealth of information on the structure and
function of cytochrome P450cam, which has since been considered as a prototype for the
cytochrome P450 gene family.35,56–58 The heme vibrational modes of the substrate-free
and substrate bound forms of both the ferric and ferrous states of P450cam have been
assigned (Table 1.2.2).36 In the high frequency region the oxidation state marker band (ν4)
occurring at 1374 cm-1 for the 6CLS substrate free P450cam (mo) and 1370 cm-1 for the
5CHS camphor bound P450cam (mos) are characteristically shifted to lower frequency as
compared to other heme proteins (Figure 1.2.2, A). This was attributed to the presence of
a strong electronic donating axial fifth ligand of the iron center, which has since been
documented to be the mercaptide of cysteine.39,59 RR studies of isotopically labeled
P450cam confirmed the presence of the Fe-S bond, exhibiting a (Fe−S) that occurs at
351 cm-1 that is observed only for the (5CHS) substrate bound form (Figure 1.2.3).56 The
6CLS substrate free P450cam spin state marker bands occurring at 1503 and 1638 cm-1
down shift to 1488 and 1624 cm-1, respectively, upon binding of substrate, indicating spin
state conversion to the 5CHS camphor bound P450cam (Figure 1.2.2, B).60
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Table 1.2.2 P450cam heme modes assignment36

Sample ν8

ν35

δCbCαCβ ν7

ν15

ν4

ν3

ν2

ν10

mo

347

379

424

678

753

1373

1503

1584

1635

mos

347

379

424

678

755

1372

1488

1570

1623

mr

345

378

418

674

747

1345

1468

1563

1601

mrs

345

378

415

674

747

1345

1466

1564

1601

mrco

352

379

423

1371

1497

1588

1372

1498

1583

mrsco

1626

Figure 1.2.2 Resonance Raman spectra of ferric P450cam and its complex with oxidized
putidaredoxin in the (A) high frequency region and (B) ν3 spin state marker regions60
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Figure 1.2.3 Resonance Raman spectrum of ferric camphor-bound P450cam is shown in
the lower curve. The insert on the right is the absorption spectrum indicating the
excitation line and on the left are the difference spectra in the region of the 351 cm-1
Raman mode56
The RR spectrum of the reduced 5CHS substrate bound form of P450cam (mrs)
exhibits anomalously low frequency ν4 (1346 cm-1) and ν3 (1466 cm-1) modes compared
to other ferrous heme proteins due to the strong π donation by the axially coordinated
cysteine thiolate.39 In the P450cam catalytic cycle (Figure 1.1.4), reduction of the
substrate bound P450cam is followed by oxygen binding resulting in the formation of a
relatively unstable dioxygen adduct of P450cam (4). RR evidence of the formation of the
dioxygen adduct were provided by Champion and coworkers,61 who observed the
strongly enhanced (O−O) mode near 1140 cm-1, and by Hu et al,62 who observed the
ν(Fe−O2) at ~540 cm-1. Interestingly, Hu and coworkers also showed that two ν(O−O)
are seen at 1139 cm-1 and 1147 cm-1 for the dioxygen adduct of the
P450cam/adamantanone complex. The detection of the two ν(O−O) modes was attributed
to the existence of two distinct substrate configurations at the binding site, this proposal
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being consistent with X-ray crystallography results reported for the adamantanone-bound
P450cam (Figure 1.2.4).63

Figure 1.2.4 The low (left traces) and high (right traces) frequency spectra of the
dioxygen adduct of adamntanone bound P450cam; trace A, 16O2; trace B, 18O2; trace C,
difference spectrum A-B62

More recently, cryogenic RR detection of the ν(16O−16O) mode occurring at 1140
cm-1 and the corresponding ν(18O−18O) at 1074 cm-1 of the oxyferrous complex of the
D251N mutant of P450cam has been reported (Figure 1.2.5).20 In the natural catalytic
cycle, the overall rate limiting step in the hydroxylation of camphor is the reduction of
the dioxygen adduct. This step is facilitated by the redox partner, putidaredoxin, which
delivers a second electron to the dioxygen-bound ferrous state of P450cam yielding the
ferric peroxo intermediate. These species do not accumulate to large enough population
due to their rapid decay under turnover conditions, complicating spectral investigation
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efforts. A cryoradiolytic reduction method, which utilizes -rays to generate free
electrons from frozen aqueous buffer containing glycerol, was developed by Symons64
and further refined by Hoffman and Davydov, and coworkers30,65–68 and has been
employed in the reduction of cryotrapped oxyferrous complex of P450cam. An EPR and
ENDOR study of cryoradiolytically reduced dioxygen adducts of wild type and D251N
mutant P450cam reported generation of the hydroperoxo and peroxo intermediates
respectively.30,65 The peroxo intermediate in the wild type protein, eluded detection
following irradiation owing to the active site structure, which facilitates delivery of the
first proton of catalysis even at 77 K yielding the hydroperoxo intermediate instead.30,65
On the other hand, in the D251N mutant P450cam, proton delivery to the active site is
hindered. This gave a distinct EPR signature characteristic of the peroxo intermediate,
which, upon annealing, converted to a spectrum consistent with the hydroperoxo
intermediate.30,65 In another study, utilization of this mutant permitted RR detection of
two isotopically sensitive modes occurring at 553 cm-1 and 792 cm-1 exhibiting shifts of
27 and 38 cm-1 respectively.20 These have been reasonably assigned to the (Fe−O) and
(O−O) of the peroxo intermediate of the cyroreduced oxyD251N samples since no H/D
shifts were observed at 77 K (Figure 1.2.6). Proton delivery to the active site in this
mutant was cleverly achieved by annealing the peroxo species to ~ 180 K; resulting in the
hydroperoxo intermediate characterized by RR spectroscopy.20 As expected H/D shifts in
the RR spectra of annealed samples of irradiated oxyD251N were observed for the
modes occurring at 564 cm-1 and 774 cm-1 consistent with the (Fe−O) and (O−O)
stretching frequencies of the hydroperoxo intermediate of the D251 mutant P450cam
(Figure 1.2.7).20 However, the highly reactive ferryl species, the equivalent of the so-
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called compound I of peroxidases, presumably formed by cleavage of the O−O bond, has
eluded spectroscopic characterization under turnover conditions.

Figure 1.2.5 The high frequency RR spectra of the dioxygen complex of the D251N
mutant of P450cam. Inset shows the difference spectra in the low frequency (Fe−O)
region20
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Figure 1.2.6 RR spectra of irradiated dioxygen adducts of P450 D251N in H2O buffer,
spectra A (16O2) and B (18O2), and in D2O buffer, spectra C(16O2) and D (18O2). The two
bottom traces shows the difference spectra of 16O2-18O2 in H2O and D2O buffers20
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Figure 1.2.7 RR spectra of irradiated and annealed (at 185 K) samples of oxyD251N in
H2O buffer, spectra A (16O2) and B (18O2), and in D2O buffer, spectra C (16O2) and D
(18O2). The two bottom traces show the difference spectra of 16O2-18O2 in H2O and D2O
buffers20
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1.3 NMR spectroscopy of heme proteins
Nuclear magnetic resonance (NMR) spectroscopy of heme proteins dates back to
1962 when the first 1H NMR of a paramagnetic cytochrome c was obtained.69,70
Researchers have since then utilized NMR methods unveiling a wealth of useful
structural and functional properties of heme proteins in solution, which is an obviously
important addition to structural determination, a realm previously dominated by x-ray
crystallography. Paramagnetic heme proteins induce enhanced relaxation of surrounding
NMR detectable signals due to electron-nuclear hyperfine interaction as a function of
nuclei distances from the heme iron.71 As a consequence the prosthetic group chemical
shifts experience isotropic shifts and are well resolved outside the diamagnetic protein
envelope. These paramagnetic shifts are composed of scalar (contact) and dipolar
(through space) contributions of the unpaired electron onto surrounding nuclei.71 The
observation of well resolved heme proton signals has allowed for the development of
NMR methods employed in the investigation of structure and dynamics in paramagnetic
proteins. One obvious drawback of these extremely short relaxation times of
paramagnetic signals is their inherent large line widths as compared to corresponding
isostructural diamagnetic molecules. This finding complicates efforts to utilize multidimensional NMR experiments in structural studies due to loss of magnetization.
Methods have, however, been developed to enhance the paramagnetic signals in heme
proteins and allowed for the assignment of heme methyl resonances. Specifically, the socalled paramagnetic signals enhancement (PASE) method was applied in 1D and 2D
experiments of high and low spin ferric complexes of the bacterial P450cam leading to
the assignment of heme 1H methyl resonances (Table 1.3.1).72
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Table 1.3.1 1H NMR assignments of the heme methyl resonances for ferric high and low
spin P450cam72

Binding of exogenous high field ligands such as the cyanide ion shifts the heme iron spin
state from high to low spin, which exhibits slightly reduced line widths and affords some
increased stability of the protein as in the case of P450cam allowing for high temperature
experiments.72 The assignment of heme proton resonances of the cyano complex of
P450cam has been reported previously (Figure 1.3.1).73

Figure 1.3.1 1H NMR of camphor-free (B), camphor bound (B) cyanoP450cam and
ferric high spin camphor bound P450cam. Insert table shows assignment of heme proton
resonances.73
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As mentioned previously, ligands in the distal pocket of the heme proteins have been
used as spectroscopic probes. Recently, Sem and coworkers have demonstrated the use of
13

C-methyl isocyanide bound to the heme iron of both bacterial and mammalian P450s as

a potential NMR probe for the elucidation of structural and electronic changes in P450
active sites.74
13

C NMR (an established powerful ally of 1H NMR) application in the study of

heme proteins has previously lagged behind mainly due to the low sensitivity and natural
abundance of the 13C nuclei, but has recently gained a lot of interest due to the impressive
development of high field NMR instruments and methods for judiciously enriching
specific carbon atoms of the heme prosthetic group. An understanding of the heme
biosynthetic pathway coupled with the developments in recombinant DNA technology
has allowed for the production of isotopically enriched prosthetic groups (Figure 1.3.2).
13

C labeled heme groups have been produced by supplementing bacterial cultures with

labeled -aminolevulinic acid (ALA), which is the first committed precursor in the heme
biosynthetic pathway (Figure 1.3.3).75–77
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Figure 1.3.2 Biosynthesis of 13C enriched (black dots) protoporphyrin IX75
Recently, an E.coli strain, the so-called HU227, lacking the δ-aminolevulinic acid (δALA) synthase gene has been exploited for the heterologous expression of P450s
harboring prosthetic groups, which are close to 100% 13C labeled at the Cm and Cα
positions (Figure 1.3.3, B), by growing the cells in the presence of [5-13C] δaminolevulinic acid (ALA).78
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Figure 1.3.3 Enrichment of the heme group at various positions using isotopically
labeled -ALA75
These developments have allowed the utilization of 13C NMR as a useful tool in the
elucidation of important structural information in paramagnetic heme proteins.13C
chemical shifts in enriched samples of ferric high spin myoglobin have been
demonstrated to report on the coordination state of the heme protein.79 Selective 13C
enrichment of the bacterial cytochrome c552 heme cofactor was achieved by expressing
the cells in minimal media supplemented with [5-13C] -ALA.80 The observation of meso
signals, which otherwise may prove to be a challenge owing to their being buried in the
protein diamagnetic region, was made possible by 13C enrichment allowing for the
application of a proton-detected single-bond correlation experiment commonly known as
1

H-13C heteronuclear multiple-quantum correlation (HMQC). This correlation of coupled

heteronuclear spins across a single bond provides connectivities between proton and
carbon nuclei of a given compound. The 2D spectrum shown in Figure 1.3.480, exhibits
crosspeaks correlated to attached nuclei at the four meso positions.
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Figure 1.3.4 1H-13C HMQC spectra of oxidized wild type (WT) and mutant AF7 [5-13C]
-ALA Hydrogenobacter thermophilus (Ht) cytochrome c55280
The assignment of meso 1H and 13C resonances was achieved by 1H-13C HMQC and 1H1

H nuclear Overhauser effect (NOE) experiments. NOE experiments involve the

magnetic interaction of nuclei spins through space or the so-called dipolar coupling in
contrast to scalar coupling in the HMQC technique. Thus the technique can be used in 3D
structural investigations establishing spatial proximity between protons. These techniques
were exploited to demonstrate the potential of the heme meso 1H and 13C resonances as
NMR probes for heme ruffling OOP deformations.80 The ability to selectively enrich the
heme core carbon opens up the possibility of utilizing NOE experiments in mapping the
active site architecture. This finding is potentially ground breaking in as much as it
allows for active site interrogation of proteins in solution, including drug metabolizing
P450s, for which few crystal structures with substrates exists.
Computational docking is routinely employed in the prediction of binding
affinities of potential substrates and inhibitors of drug metabolizing P450s. Essentially a
lowest energy P450-substrate/inhibitor complex is obtained after optmization, which

30
involves calculatation of energies of interaction between protein and ligand.
Unfortunately, efficient and accurate prediction of protein-ligand interactions by these
computational methods is compromised by the inherent flexibility of drug metabolism
P450s binding sites, such as in CYP2D6, which metabolizes 20-30% of all drugs. NOE
experiments on P450s bearing heme groups or active site residues with judiciously placed
isotopic labels could be exploited in defining solution phase active site structure.
Specifically, NOE measurements of interatomic distances between reference points on
the heme group and active side residues will provide a map of the substrate-free active
site. Employing several substrates in the pocket and obtaining NOE derived distances
between reference points (13C- enriched heme core carbons and /or 13C-labeled amino
acid residues in the active site) and substrate protons will provide information on the
flexibility/rigidity of P450s active site. Inasmuch as mapping of these flexible active sites
is computationally demanding, employing expereimentally derived interatomic distances
in docking routines would speed the process and potentially lead to more accurate
pridictions of substrate or inhibitor interactions with the drug metabolizing P450.
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1.4 Specific issues to be addressed in this work
1.4.1 Utilization of chemically inert substrates to stabilize compound I intermediates
of P450s
In the widely accepted natural catalytic cycle, the highly reactive Fe(IV)=O
porphyrin π-cation (6) radical or the so called compound I intermediate, which results
from a proton assisted scission of the O-O bond has eluded spectroscopic
characterization, presumably owing to its inherently short life time and has recently
earned the “mystery” title.81 In recent years several experimental approaches have been
used to artificially produce compound I and investigate its electronic structure and
reaction kinetics.82–91 The application of spectroscopic methods in the characterization of
these species has been reviewed recently.92,93 An artificially produced compound I form
of CYP119 has been reported to be an Fe(IV)=O-porphryin π-cation radical, exhibiting a
ferryl iron spin (S=1) that is antiferromagnetically coupled to the S` = ½ of the porphyrin
radical, giving a total spin of ½, equivalent to the ground state of chloroperoxidase
compound I.85 The obvious interest in this highly reactive intermediate calls for the
development of effective capture strategies (or trapping experiments), ideally in the
natural catalytic cycle leading to the subsequent characterization of the “true” compound
I form of these biological catalysts. The present work is focused on efforts to generate,
trap and spectroscopically characterize the elusive potent compound I intermediate of
P450s under turn over conditions. Specifically, utilization of chemically inert substrates
of P450s were investigated as a possibly viable method of stabilizing the transient and
highly oxidizing Fe(IV)=O porphyrin π-cation radical intermediate occurring in the P450
catalytic cycle (6 in Figure 1.1.4) allowing for its characterization by RR methods. This
strategy was initially applied to the P450cam system utilizing perfluoroadamantanone
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(PFA) as a chemically inert substrate and later to the thermophilic bacterial P450,
CYP119, where perfluorinated long chain fatty acids were employed as inert substrates.

1.4.2 NMR spectroscopy characterization of isotopically labeled P450s
This study aims at employing NMR methods to allow solution phase active site
structure determination of P450s bearing isotopically labeled heme groups. Specifically,
NOE experiments will be exploited to derive distances between heme reference points
and substrate protons providing enhanced active site definition in the solution phase.
NOE measurements will also be employed to establish spatial proximity between the
heme reference points and active site residues.

13

C-enriched P450 active side residues

will also be exploited as reference points for establishing spatial proximity to substrate
protons. Employing different substrates and derivation of distances between substrate
protons and active site reference points will provide information on the flexibility and/or
rigidity of the P450 active site. An extension of this approach to important drug
metabolizing enzymes such as CYP2D6 has the potential to furnish valuable
experimental restrictions in docking routines, which are commonly employed in
determining the relative affinities of drug candidates. A recent and novel approach for the
isotopic labeling of the prosthetic group in heme proteins has been exploited to produce a
13

C analogue of the soluble bacterial cytochrome P450cam.78 Briefly, the HU227 strain of

E. coli that lacks the δ-aminolevulinic acid (δ-ALA) synthase gene was employed in the
heterologous expression of P450cam harboring a prosthetic group 13C labeled at the Cm
and Cα positions (Figure 1.3.3) by growing cells in the presence of [5-13C] δ-ALA
synthesized in four steps from [2-13C] glycine.94,95 This system has been employed in a
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“proof of principle” exercise for the strategy of defining active site structure using NMR
methods.
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CHAPTER 2 UTILIZATION OF FLUORINATED SUBSTRATES TO
STABILIZE COMPOUND I INTERMEDIATES OF CYTOCHROME P450
2.1 Perfluorinated substrates of P450cam
2.1.1 Introduction
Initial efforts to employ chemically inert substrates as a possible strategy to
stabilize and capture the compound I forms of P450s were performed using
perfluoroadamantanone (PFA) 96 and the bacterial cytochrome P450cam.The major pitfall
of using PFA as a P450cam substrate is its apparent lack of solubility in aqueous buffer.
The alcohol derivative of PFA denoted PFA-ol, however has been reported to be soluble
in a 1:1 methanol-water solution.97 Owing to limited quantities of PFA, optimization of
the reduction procedure to obtain PFA-ol was done using 2-adamantanone. The product
of 2-adamantanone reduction, 2-adamantanol, dissolved in a methanol/water solution (1:1
ratio by volume), was shown to bind substrate-free P450cam with almost 100% spin state
conversion of the heme from low spin to high spin (Figure 2.1.1). It was also established
that reduction of PFA resulted in an impure product, which exhibited partial binding to
substrate-free P450cam (Figure 2.1.2). The suggested reasons for the partial binding
observed were thought to be false substrate stock concentration (due to the impure
substrate) and that possibly PFA-ol only binds partially to P450cam as an inherent
characteristic (thus not achieving 100% spin state conversion, see Figure 2.1.2). This
required further optimization of the PFA reduction procedure; however the major setback
was the dwindling quantities of stock starting material. In view of this drawback, 2adamantanone was used for further optimization of the reduction reaction and the results
of such efforts are discussed in the following sections.
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Figure 2.1.1 The UV-Vis spectra of 2-adamantanol binding to substrate-free P450cam

Figure 2.1.2 The UV-Vis spectra of F-adamantanol binding to substrate-free P450cam
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2.1.2 Optimization of PFA reduction procedure
The optimization of PFA reduction was done using 2-adamantanone following the
published procedure of Adcock et al. (1996).97 Specifically, a 15 mg portion of 2adamantanone was weighed and transferred to a glass vial. The vial was degassed by
flushing with H2O/O2-free N2 gas for about 10 minutes, followed by addition of 370 µL
of diethyl ether under N2 using a gas tight syringe. A solution of 1 M LiAlH4 in diethyl
ether (130 µL) was then added to the solution of 2-adamantanone in diethyl ether. The
vial was stirred for 2 h at about -2 °C and at room temperature overnight followed by
addition of 100 µL of absolute ethanol under N2. The mixture was stirred for another 15
minutes and then poured into a solution of 5 g of 98% H2SO4 (500 µL). The product was
then extracted in diethyl ether and dried over P2O5 in a desiccator. The white product was
sublimed at about 165 °C to give about 90% of pure 2-adamantanol (Figure 2.1.3). The
improvement in the yield of 2-adamantanol (75 to 90%) suggests that an inert
environment may be a required condition for PFA reduction.
Reduction of PFA following the procedure just described gave transparent
crystals stuck on the glass wall after evaporation of the ether extract (probably about 5
mg). Efforts to sublime this product were unsuccessful as nothing was recovered at the
cold finger possibly due to the small amount used. Considering that when 150 mg of PFA
was used, about 60 mg of impure product was obtained and when further scaled down to
60 mg only 15 mg was realized, utilizing 15 mg (as in the case described above) proved
impractical for this deceivingly simple procedure. Also given that the reaction works
excellently with 2-adamantanone giving yields of up to 90% pure 2-adamantanol even on
the same small scale described, it may be argued at this point that 2-adamantanone has a
different chemistry as compared to PFA and as such cannot be ideal for optimizing the
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PFA reduction reaction. As mentioned previously, the dwindling quantities of PFA have
proven to be challenge in these reactions. In an effort to advance the running aim of using
chemically inert substrates to stabilize the compound I forms of P450s, an alternative
route using CYP119 and perfluorinated fatty acids as possible inert substrates was
adopted.

Figure 2.1.3 H NMR of 2-adamantanone (top trace) and 2-adamantanol (bottom trace) in
CDCl3
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2.1.3 Cytochrome P450 119 (CYP119)
CYP119, a thermophilic protein from the archaebacteria Sulfolobus solfataricus,
has been shown to be stable under extreme temperatures and pressure.98 The reported
melting temperature (90 °C) is 40 °C higher than the mesophilic P450cam and the
enzyme has been demonstrated to exhibit hyperbaric stability, withstanding pressure of
up to 200 MPa.98–100 Crystal structure studies of CYP119 have documented the presence
of extended aromatic clusters not observed in mesophilic proteins and have been thought
to confer the inherent thermal and pressure stability (Figure 2.1.4).99–102 The melting
temperature was shown to decrease by approximately 10 °C when the aromatic clusters
were disrupted by either a single or double mutation.103

Figure 2.1.4 Crystal structure of CYP119 showing the aromatic residues thought to
confer thermal stability103
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Determination of the underlying factors conferring these unusual properties exhibited by
thermophilic proteins can possibly be exploited in the engineering of stable mesophilic
biocatalysts. In addition, the demonstrated structural stability of these proteins allows for
mechanistic investigations, which are otherwise almost impossible in mesophilic P450s.
In fact, at room temperature, the active site of such thermostable enzymes is possibly
rigid, resulting in a possible slowdown of individual steps in the catalytic cycle.104
However, the dioxygen complex of the substrate free CYP119 was shown to be unusually
unstable with an autoxidation rate of 0.08 s-1 at 5 °C.105As would be expected, the
substrate free dioxygen adduct of P450s are less stable compared to species in complex
with substrate. However the observation in CY119 has in addition, been linked to the
active site architecture in which the heme iron is more in plane than in the bacterial
P450cam. Moreover a large deviation of the Fe−S bond from the heme axis and unusual
ruffling of the prosthetic group have been proposed to account for the observed fast
autooxidation rate.105 Structural investigations of the active sites of CYP119, P450cam
and CYP102 showed that the thermophilic enzyme exhibits an open conformation with
higher flexibility and greater solvent access than P450cam, but similar to CYP102.98 On
the other hand, the compound I form of CYP119 produced by laser flash photolysis of the
corresponding compound II (a product of peroxynitrite oxidation of CYP119) species has
been reported to be stable with a lifetime of ~ 200 ms at 20 °C.91 However, later studies
on peroxynitrite oxidation of CYP102 have shown that the intermediate generated is an
iron-nitrosyl complex rather than the FeIVoxo.106 More recently, however, Green et al
have utilized meta-chloroperoxybenzoic acid (m-CPBA) to generate the compound I
intermediate in 75% yield permitting its spectroscopic and kinetic as discussed briefly
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under Section 1.4.1.85 These findings make the thermophilic protein an attractive
alternative to the ongoing work of using chemically inert substrates to stabilize what has
been referred to as the Holy Grail of P450 intermediates or the so-called compound I.91
The natural substrate for CYP119 remains unknown. However it has been shown
to bind fatty acids ranging from C8-C20 in carbon chain length with lauric acid
considered as a surrogate substrate exhibiting the highest binding affinity (Table
2.1.1).107,108

Table 2.1.1 The binding affinities of various surrogate substrates of CYP119107

Lauric hydroxylation at 37 °C with chemically produced compound I species of CYP119
have been reported to occur at positions 1, 2 & 3.107 Based on these observations, it
is now being postulated that the perfluorinated analogues of these long chain fatty acids,
which are commercially available, might possibly act as chemically inert substrates of
CYP119. Chemical reduction of the ferric substrate-bound CYP119 (using perfluorinated
fatty acids as inert substrates) was followed by binding oxygen to form the dioxygen
adduct (4 in Figure 1.1.4). Cryoradiolysis of the dioxygen adducts of substrate bound
CYP119 was employed in an attempt to generate, stabilize and spectroscopically
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characterize the subsequent intermediates occurring in the catalytic cycle, of particular
interest being the compound I form (6) of CYP119.
2.2 Materials and Methods
The plasmid encoding the CYP119 gene was kindly provided by the Sligar group
and competent BL21 E.coli cells were purchased from Biolabs. Tryptone, yeast extract
and Lauria-Bertani (LB) agar, used in the expression procedure described below, were
purchased from Mo Bio Laboratories Inc. Lauric acid and ethylene glycol were obtained
from Sigma Aldrich. Perfluorododecanoic acid (PFLA), perfluorodecanoic acid (PFDA)
and perfluorooctanoic acid (PFOA) were purchased from Alfa Aesar and used without
further purification. Ethylene glycol-d4 and D2O were purchased from Cambridge
Isotopes.

2.2.1 CYP119 Expression and Purification
P450s are routinely produced by heterologous expression utilizing E.coli cells.109
Basically, a self-replicating circular DNA, called a plasmid, bearing the sequences coding
for the P450 of interest is introduced into E. coli competent cells (cells treated with CaCl2
to make them porous; so they can take up foreign DNA) by a process known as
transformation. The cells are then exploited to amplify the plasmid to produce large
quantities of it. Usually, the plasmid contains sequences that code for an antibiotic
resistance protein, such that only competent cells containing the foreign plasmid can
grow on media supplemented with the respective antibiotic. Most commonly, the
expression vectors (plasmids) contain inducible sequences upstream of the gene of
interest, for example, the pCWori+ vector,110 which is widely used for P450

42
expression,111 exhibits sequences of a lac operon. The lac operon is involved in lactose
metabolism in bacteria and its transcription is shutdown by a DNA binding protein
known as a lac repressor protein, the operon is turned on in the presence of a lactose
metabolite, allolactose, which binds the lac repressor protein. In the pCWori+, the lac
operon, situated upstream of the P450 gene in the promoter region, is induced by addition
of isopropyl β-D-1-thiogalactopyranoside (IPTG), an allolactose mimic, which binds to
the lac repressor protein and turns on the lac operon. Thus, it induces expression of the
downstream P450 protein.
The CYP119-containing plasmid (provided by Sligar group at Urbana
Champagne, IL) was transformed into BL21 cells (Biolabs) following the manufacturer’s
protocol. A single colony from the overnight grown CYP119/BL21-LB agar plate was
used to inoculate 10 mL of LB broth (supplemented with 100 g/mL ampicillin) as a
starter culture for the expression of CYP119 performed according to a previously
published procedure with minor modifications.98 Briefly, cells were grown overnight at
37 °C and 250 rpm and used as 1 % inoculum in 10 mL of 2YT media (16 g tryptone, 10
g yeast extract and 5 g NaCl per 1L) supplemented with 100 g/ml ampicillin. The 10
mL culture was incubated at 37 °C and 250 rpm until the OD at 600 nm was about 0.3
(about 2-3 h). This early log phase culture was used to inoculate 1L of 2YT media (also
supplemented with 100 g/mL ampicillin) grown at 37 °C and 250 rpm for 20 h. The
cells were harvested by centrifugation at 8000 rpm for 10 minutes at 4 °C, giving an
average of 12.5 g/L of wet cells. Cells were stored at -80 °C until needed.
Cells were thawed and resuspended in 4 volumes (4 mL/g of wet cells) of lysis buffer (50
mM Tris/HCl pH 8.0, 1mM EDTA, 4 mg/mL lysozyme, 16 U/mL DNase, 4 U/mL
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RNase) and stirred gently for 4 h at 4 °C followed by centrifugation at 20 000 rpm for 1 h
to remove cell debris. The supernatant was incubated at 75 °C for 15 minutes to remove
some of the contaminating bacterial proteins. The precipitated bacterial proteins were
spun down at 8000 rpm for 30 minutes and the supernatant slowly saturated to 40 %
(NH4)2SO4 (243 g/L) and stirred gently for an hour at 4 °C. The precipitated proteins
were removed by centrifugation at 8000 rpm for 30 minutes and the crude soluble
CYP119 was precipitated following 100 % saturation with (NH4)2SO4 (469 g/L). The
CYP119 pellet was resuspended in a minimum volume (~ 5mL) of 10 mM phosphate
buffer (KPi), pH 7.2) and loaded onto Bio-gel P-100 column (3 x 40 cm) equilibrated and
resolved in the same buffer. Fractions with Rz (A416/A280) values greater than 0.5 were
pooled, concentrated and loaded onto DEAE 53 anion exchange column (3 x 12 cm)
equilibrated in 10 mM KPi, pH 7.2. The column was washed with 6 column volumes
(CV) of 10 mM KPi, pH 7.2 and the protein was eluted with a 10-100 mM KPi gradient
at pH 7.0. Fractions with Rz > 1.5 were pooled and concentrated giving an average of 0.5
mL of ~ 0.4 mM (per L of culture) of pure substrate free CYP119 (SFCYP119) with a
low spin state heme iron (Figure 2.2.1).
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Figure 2.2.1 The absorption spectra of the ferric substrate free form of CYP119

2.2.2 Identification of a suitable inert substrate
Lauric acid and its perfluorinated analogue were the first candidates due to the
reported high binding affinity of lauric acid.108 Concentrated (12 mM) substrate stock
solutions were dissolved in methanol and used to titrate substrate-free CYP119
(SFCYP119). Substrate binding to SFCYP119 was monitored by spin state associated
shifts of the Soret band from around 416 nm down to 392 for the substrate free (low
spin) and bound (high spin) forms, respectively. UV-Visble spectra were obtained using a
Hewlett-Packard Model 8452 Diode Array Spectrophotometer.
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2.2.3 Preparation of Oxy complexes
Protein samples were prepared by mixing 20 L of 1 mM SFCYP119 (in 100 mM
KPi, pH 8.0, 0.3 M NaCl), 7 L of glycerol (v/v) and 3 L of 25 mM PFDA (or Lauric
acid) dissolved in ethylene glycol and transferred to an NMR tube. Deuterium
substitution was achieved by equilibrating protein samples in D2O KPi buffer, pD 8.0, 0.3
M NaCl for 2 days at 4 °C. Preparation of protein samples was essentially the same as
above, with the only exception being utilization of deuterated glycerol and ethylene
glycol. An in-house vacuum line assembly shown below was used in the preparation of
dioxygen adducts of CYP119 (Figure 2.2.2). The NMR tube containing the sample was
frozen in liquid N2 and evacuated by opening valve1, while valves 2 and 3 remained
closed. Small amounts of argon were added to the frozen sample by closing valve 1 and
opening valve 2. The liquid N2 bath was removed from the sample and the sample was
thawed and vortexed. This evacuation process was done 4 times. While the sample is
still immersed in liquid N2, in the 4th evacuation cycle, valves 2 and 3 are both opened,
such that a positive pressure is maintained. This is followed by dismantling of the
removable part allowing addition of Na2S2O4 and O2 saturated buffer. The ferrous form
of PFDA-CYP119 was prepared by incubating the respective ferric form with 1 L of 12
mg/mL Na2S2O4 for about 30 minutes under argon atmosphere while formation of ferrous
LA-CYP119 required 45 minutes incubation with 2 L of the dithionite solution.
Reduction was monitored by changes in the Q-band region of the absorption spectra, the
band near 550 nm is characteristic of the ferrous form of the heme protein (Figure 2.2.3).
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Figure 2.2.2 Schematic of the vacuum line assembly utilized in the preparation of
dioxygen adducts of CYP119

Figure 2.2.3 The absorption spectra of ferric (bottom trace) and ferrous (top trace) lauric
acid bound CYP119
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The reduced samples were cooled down to – 20 °C by immersing the NMR tube in an
ethanol/dry ice bath for 2 minutes while a positive argon pressure was maintained.
Approximately 70 L of cold (-20 °C) 16O2-saturated buffer [100 mM KPi , pH 8.0, 30 %
glycerol] was added to the cooled reduced protein followed by rapid mixing (using a
vortex) for 10 s. The oxygenated samples were immediately frozen in liquid N2.
Preparation of 18O2 adducts was achieved by rapidly mixing (10 s vortex) the reduced
samples with ~ 100 L of 18O2-saturated buffer. The process was repeated for samples
equilibrated in D2O KPi buffer with 16O2/18O2-saturated D2O KPi buffer. The formation
of the dioxygen complex of substrate bound CYP119 was verified by RR at liquid N2
temperature (vide infra).
2.2.4 Cryoradiolytic reduction of CYP119 oxy complexes
Cryoradiolytic reduction of the oxy complexes of CYP119 was performed as reported
earlier112 with minor modifications. Specifically, frozen samples of oxy-ferrous CYP119
were irradiated with 60Co γ rays at 77 K and a dose rate of 92 Gy/min. The total
irradiation time was 330 minutes, which translates to a total dose of ~ 3 Mrad or 30 kGy.
Samples were kept in liquid N2 before, during and after irradiation. Irradiated and
annealed (vide infra) irradiated samples were probed by EPR and RR spectroscopic
methods
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2.2.5 Resonance Raman Spectroscopy of CYP119 intermediates
Resonance Raman spectra were obtained using a Spex 1269 spectrometer
equipped with a CCD detector (Spec 10 from Princeton Instruments), at liquid N2
temperatures (77 K). The excitation lines employed for the oxyferrous samples before
and after irradiation were 413 nm (Coherent Sabre Kr ion laser) and 441.6 nm (Kimmon
Model IK4153RC He:Cd laser), respectively. Fenchone was used to calibrate all spectra,
which were processed with Grams 32/AI (Galactic Industries, Salem, NH). Rayleigh
scattering was removed by use of an appropriate Notch filter from Kaiser Optical. The
power at the sample was approximately 1.5 mW. The NMR tube containing the sample
was spun and the RR spectra were collected at liquid N2 temperature using 180 (back
scattering) geometry in combination with a cylindrical lens, which focuses the laser beam
on the sample as a line image to avoid local heating (Figure 2.2.4).113,114

Figure 2.2.4 Schematic of RR instrumentation
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2.3 Results and Discussion

2.3.1 Inert substrate-CYP119 binding titrations
As mentioned previously, substrate binding was monitored by observing shifts of
the Soret band from 416 nm (for substrate free protein) to 391 nm (substrate bound). All
the fatty acids employed were soluble in methanol; however, when the SFCYP119 was
titrated using concentrated (12 mM) methanolic stock substrate solutions no significant
spin state changes were observed in the absolute visible spectra of the protein even at
elevated temperatures (37 °C) (Figure 2.3.1 and Figure 2.3.2). The difference spectra,
however shows substrate binding associated spin state shifts [Figure 2.3.3 (data shown
for lauric acid and its perfluorinated analogue)].

Figure 2.3.1 The absorption spectra of ~ 0.2 M SFCYP119 titration with LA (12 mM in
ethylene glycol) at 37 °C; insert shows the molar ratio
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Figure 2.3.2 The absorption spectra of ~ 0.2 M SFCYP119 titration with PFLA (12 mM
in ethylene glycol) at 37 °C; insert shows the molar ratio

Figure 2.3.3 The difference spectra of SFCYP119 titration with 12mM LA (A) and
PFLA (B) dissolved in methanol at 37 °C
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As alluded to earlier, exogenous ligands coordinated to the heme iron on the distal
site can be exploited to spectroscopically investigate structural details in the active site.
The CO ligand was employed as a spectroscopic probe to monitor structural changes
associated with substrate binding in heme proteins. Specifically, changes in the
(Fe−CO) stretching frequency of the ferrous CO bound form of the enzyme can be used
as evidence of substrate binding. The substrate free and bound samples of CYP119 were
bubbled with CO, reduced by sodium dithionite and the (Fe−CO) frequency monitored
by resonance Raman spectroscopy. Only slight changes in the (Fe−CO) mode were
observed for CYP119 “bound” to lauric acid (LA), its perfluorinated analogue (PFLA)
and perfluorodecanoic acid (PFDA), suggesting that the substrates may not be in close
enough proximity to the heme group to cause any significant perturbation in the
(Fe−CO) stretching mode (Figure 2.3.4). This is in contrast to the spectroscopic changes
observed for the bacterial protein, P450cam, where the Fe−CO) stretching mode
exhibits a 20 cm-1 shift from 464 to 484 cm-1 upon binding of substrate.36,115 On the other
hand, the v(C-O) modes of PFLA and PFDA bound CYP119 occurring at 1950 and 1953
cm-1 are upshifted by about 4 and 6 cm-1 respectively, suggesting slightly different
substrate structure effects on the CO fragment (Figure 2.3.4).
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Figure 2.3.4 RR spectra in the Low (left traces) and high (right traces) frequency regions
of the ferrous CYP119-CO forms. SF; substrate free, LA; lauric acid bound, PFLA;
perfluoro lauric acid bound and PFDA; perfluorodecanoic acid bound.
Significant spin state changes were however observed when ~ 0.6 M SFCYP119
was incubated in 100 mM KPi, pH 7.0, 60% glycerol and ~2.5 mM LA at 50 °C (Figure
2.3.5). PFLA on the other hand was not soluble in glycerol, but dissolved in ethylene
glycol; however spectral changes were observed for the SFCYP119 incubated in 100 mM
KPi with 30 % ethylene glycol (Figure 2.3.6), suggesting that ethylene glycol might be
competing as a substrate. No significant spin state changes were observed when
SFCYP119 (in 100 mM KPi with 60 % glycerol) was titrated with volumes of ethylene
glycol not exceeding 3 % at 50 °C (Figure 2.3.7). Under these conditions
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perfluorodecanoic acid (PFDA) “dissolved” (at 50 °C the fatty acid melts) in ethylene
glycol was shown to bind SFCYP119 with observable spin state changes (Figure 2.3.8).
Specifically, a concentrated stock solution (50 mM) of PFDA “dissolved” in ethylene
glycol was used to titrate ~ 0.6 μM SFCYP119 in 100 mM KPi, pH 7.0, 60 % glycerol in
5 μL increments up to 20 μL, which translates to less than 1 % of ethylene glycol (v/v).

Figure 2.3.5 The absorption spectra of ferric substrate free (black trace), ferric LA bound
(blue trace) and ferrous-CO (red trace) forms of CYP119
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Figure 2.3.6 The effects of ethylene glycol and glycerol on the absorption spectra of
ferric SFCYP119 at 50 °C
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Figure 2.3.7 Absorption spectra of SFCYP119 titration with ethylene glycol obtained at
50 °C

Figure 2.3.8 The absorption spectra of ferric SF (red trace) and PFDA bound CYP119 at
50 °C. The insert shows changes in the Q-bands region upon substrate binding.
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2.3.2 RR spectroscopy of substrate bound CYP119
The high frequency resonance Raman spectra of the ferric substrate free and
bound samples obtained at ~ 50 °C shows the corresponding partial spin state changes
observed by absorption spectroscopy (Figure 2.3.9). The spin state marker 3 occurring at
1502 cm-1 for the low spin SFCYP119, exhibits a clear down shift to 1488 cm-1
(characteristic of a 5 coordinate high spin heme iron) upon substrate binding. As is
evident in trace B of Figure 2.3.9, lauric acid binding causes the most significant (greater
than 50%) spin state changes, a finding that is consistent with its high binding affinity
(1.2 ± 0.2 M).107,108 In contrast PFDA results in a less significant spin state conversion,
which may be due to the lower binding affinity of its non fluorinated analogue, decanoic
acid (28 ± 2 M).107 However the spin state conversions in this current work observed at
50 °C are significantly higher as compared to those reported for styrene-bound CYP119
at 70 °C.116 The observed recalcitrance of CYP119 to spin state changes upon substrate
binding is thought to be due to an unusually strong hydrogen bonding network stabilizing
the distal water ligand in addition to the active site architecture discussed earlier101
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Figure 2.3.9 The high frequency region of resonance Raman spectra obtained with
406.7nm excitation at ~50°Cfor the SFCYP119 (A), Lauric acid bound CYP119 (B) and
PFDA bound CYP119 (C).
Given that the optimal growth temperature for the thermophilic bacteria from which the
CYP119 gene was cloned is between78-86 °C, 98,117,118 it may be possible to obtain 100%
spin state conversion with lauric acid binding at temperatures greater than 70 °C
(assuming that lauric acid does not decompose). Although this might be crucial in
explaining substrate binding in this thermophilic P450, it offers no advantage to our
current efforts to stabilize and capture the elusive compound I form of CYP119, both
which are performed at cryogenic temperatures.
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The corresponding low frequency region spectra indicate changes to the modes
associated with propionate and vinyl groups upon substrate binding. Specifically, lauric
acid binding activates a second propionate bending mode occurring at 371 cm-1 (Figure
2.3.10, trace B), which have been documented recently (in P450cam) to be degenerate
with an out of plane 6 mode.22 The lower frequency vinyl bending mode (rather
accurately described as pyrrole I or II deformations with vinyl contributions) occurring
around 405 cm-1 is activated and up shifted with 2 and 3 cm-1 upon binding of LA and
PFDA respectively. Consistent with the spin state conversion observed in the high
frequency region upon binding of PFDA, activation of the lower frequency “vinyl
bending mode” is less significant as compared to binding of LA.

Figure 2.3.10 The low frequency resonance Raman spectra of ferric SF (A), LA bound
(B) and PFDA bound (C) forms of CYP119 at ~50 °C
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Interestingly, even with the observed spin state changes at 50 °C, no significant changes
were observed in the (Fe-CO) upon substrate binding as noted earlier (Figure 2.3.11).
Similar behavior has been observed in another bacterial cytochrome P450 isolated from
Bacillus megaterium, the so-called P450BM3.33

Figure 2.3.11 The resonance Raman spectra of the ferrous-CO for the substrate free (A),
LA bound (B) and PFDA bound (C) CYP119 at 50 °C.

Although substrate binding in CYP119 does not result in a full spin state
conversion to the high spin as observed in the mesophilic P450cam, T1 NMR
experiments of CYP119 with bound styrene has shown it to be within 4.4-4.5 Å of the
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heme iron.116 On the other hand, the reported binding affinity of styrene is significantly
lower than that of lauric acid, and indeed the hydroxylation of lauric acid, which has been
studied extensively, suggests that it sits within reaction distance to the heme iron.107,108

2.3.2.1 RR characterization of CYP119 dioxygen adducts before cryoradiolytic
reduction
The formation of oxy ferrous complexes of substrate bound (LA/PFDA) CYP119
were confirmed by RR spectroscopy at 77 K. The high frequency spectra of the oxy
complex of LA bound CYP119 shown in Figure 2.3.12, exhibits a broad band centered
around 1135 cm-1, which has previously been interpreted as arising from the (16O-16O)
stretching frequencies of different conformers of the Fe-O-O fragment. Indeed this mode
exhibits isotope sensitivity shifting down by about 64 cm-1 upon 18O2 substitution, as can
be clearly seen in the difference spectrum in the top trace of Figure 2.3.12, a finding that
is consistent with previously reported spectra of trapped O2 adducts.20,119 The
corresponding RR spectra of LA bound CYP119 in D2O buffer (Figure 2.3.13) suggests
hydrogen bond interactions in the distal pocket between the bound dioxygen with either
side chain residues or water molecules as evidenced by the H/D shift (2-3 cm-1) of the
both 18O2 and 16O2 stretching modes. The dioxygen adduct of CYP119 in complex with
the fluorinated substrate, PFDA exhibited similar RR spectral behavior in the high
frequency region, with both (16O−16O) and (18O−18O) only slightly shifted down
(2 cm-1) and centered around 1133 and 1068 cm-1 respectively (Figure 2.3.14). As
observed for the LA bound dioxygen adduct of CYP119, both the 16O2 and 18O2
stretching frequencies also demonstrated isotope sensitivity upon deuterium substitution
of exchangeable protons (Figure 2.3.15), suggesting an H-bonded dioxygen species in the
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distal pocket. A calculated model structure of the dioxygen adduct of CYP119 in the
absence of substrate revealed similarities with the oxygenated intermediate of CYP101
with the conserved threonine residue at position 213 within hydrogen bonding distance to
the bound oxygen.105 In addition ,the active site water molecules, visualized in the high
resolution crystal structure of ligand free CYP119, are possible hydrogen bond donors,
these have been proposed to play a role in the catalytic scission of the bound dioxygen.101

Figure 2.3.12 The high frequency RR spectra of the oxy ferrous complex of LA bound
CYP119 in H2O buffer collected using the 413 nm excitation line at 77K
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Figure 2.3.13 The high frequency RR spectra of the oxy ferrous complex of LA bound
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K
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Figure 2.3.14 The high frequency RR spectra of the oxy ferrous complex of PFDA
bound CYP119 in H2O buffer collected using the 413 nm excitation line at 77K
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Figure 2.3.15 The high frequency RR spectra of the oxy ferrous complex of PFDA
bound CYP119 in D2O buffer collected using the 413 nm excitation line at 77K

The low frequency RR spectra of the dioxygen adduct of LA and PFDA bound
CYP119 in H2O and D2O buffers are shown in Figures 2.3.16-2.3.19. Although spectral
noise complicates identification of the (Fe−O2) mode, the difference spectrum of
16

O2−18O2 provides some evidence for the (Fe−16O2) and (Fe−18O2) modes in the range

expected for thiolate ligated heme proteins.62 The LA bound CYP119 (Fe−16O2) occurs
around 533 cm-1 and exhibits sensitivity to 18O2 isotopic substitution, shifting with about
34 cm-1 as expected (Figure 2.3.16). Interestingly, the difference spectrum of 16O2−18O2
in D2O reveals an unusual distinct H/D shift, with both the (Fe−16O2) and (Fe−18O2)
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modes shifting up by about 3 cm-1 upon deuterium substitution (top trace in Figure
2.3.17), possibly suggesting H-bonding to the proximal oxygen. This observation is
unusual in as much as such H/D shifts are reportedly small and normally not observable
for the (M−O2) modes.28,29,120–122 The difference spectra of 16O2−18O2 of the PFDA
bound CYP119 dioxygen complex in H2O buffer, shown in Figure 2.3.18, exhibits
positive and negative broad bands centered around 524 and 490 cm-1, which makes it
almost impossible to assign them to the stretching Fe –O modes. On the other hand, the
dioxygen adduct of PFDA bound CYP119 in D2O buffer show similar behavior to the LA
bound dioxygen species in the Fe−O stretching frequency region (Figure 2.3.19), with the
16

O2 and 18O2 slightly upshifted by 3 and 5 cm-1 respectively, suggesting sensitivity of the

bound ligand to different substrates. This observation has been reported earlier for
CYP101, in which the (Fe−16O) mode for the camphor bound enzyme, occurring around
541 cm-1 was down shifted to 537 cm-1in the dioxygen complex of adamantanone-bound
P450cam.62 In summary, the RR data in both the high and low frequency spectral regions,
document the successful formation of the dioxygen species of substrate bound CYP119 at
liquid N2 temperature. Cryoradiolytic reduction of this species is expected to yield the
peroxo/hydroperoxo intermediates (vide infra), which precedes the proton assisted
scission of the O-O bond resulting in the generation of the compound I.
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Figure 2.3.16 The low frequency RR spectra of the oxy ferrous complex of LA bound
CYP119 in H2O buffer collected using the 413 nm excitation line at 77K
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Figure 2.3.17 The low frequency RR spectra of the oxy ferrous complex of LA bound
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K
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Figure 2.3.18 The low frequency RR spectra of ferric PFDA bound CYP119 and its 16O2
and 18O2 adducts in H2O buffer
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Figure 2.3.19 The low frequency RR spectra of the oxy ferrous complex of PFDA bound
CYP119 in D2O buffer collected using the 413 nm excitation line at 77K.

2.3.2.2 RR characterization of irradiated dioxygen adducts of CYP119
Cryoradiolytic reduction was employed to deliver another electron to the
dioxygen adducts of substrate-bound CYP119 in an attempt to generate the subsequent
intermediates occurring in the P450s catalytic cycle. Briefly, oxy-ferrous samples of LAand PFDA-bound CYP119 were irradiated, using 60Co, at a dose rate of 92 Gy/min for
330 minutes. The irradiated substrate-bound CYP119 samples were characterized by RR
at 77 K using the 442 nm excitation line, which is expected to selectively enhance the
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peroxo- and hydroperoxo- intermediates. The low-frequency RR spectra of irradiated
dioxygen adducts of LA-bound CYP119, in H2O and D2O buffers, are shown below
(Figures 2.3.20 and 2.3.21). The difference spectra of 16O2-18O2, in both H2O and D2O
buffers, shows residual oxy-ferrous complex of LA-bound CYP119 (top spectra in
Figures 2.3.20 and 2.3.21). This is attributable to incomplete reduction of the oxy-ferrous
samples during irradiation, probably because of weakening of the 60Co radiation source.
Additionally, a negative band around 752 cm-1, is observed in both H2O and D2O
samples. On the other hand, the 16O2-18O2 difference spectra of irradiated samples of
PFDA-bound oxy-ferrous CYP119 show no evidence of residual dioxygen adducts;
neither, unfortunately, is there any evidence for the expected peroxo/hydroperoxo
intermediates (top trace of Figures 2.3.22 and 2.2.23). The band around 752 cm-1, for the
LA-bound samples, might possibly be arising from the (18O−18O) mode, however, no
corresponding (16O−16O) positive bands, expected in the 750-800 cm-1 region,20 were
detected, making unequivocal assignment impossible. In fact, this band might be a heme
mode coming from residual ferric form as observed in the low-frequency region of the
spectra before irradiation (Figure 2.3.16). In addition, no isotopic sensitive bands were
observed in the 520-580cm-1 region, where the (Fe−O2) mode is expected for the
peroxo/hydroperoxo intermediates of P450s.20 The inability to detect either the
peroxo/hydroperoxo intermediates, by RR at 77 K, might be due to warming, by the laser
beam, at the surface of the sample. This, presumably, results in the decay of
peroxo/hydroperoxo intermediates, through proton transfer and O-O bond cleavage
leading to compound I and hydroxylation of LA. On the other hand, warming up
irradiated samples of the dioxygen adducts of CYP119 in complex with a chemically
inert substrate, PFDA, might result in accumulation of compound I on the surface of the
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sample, however, to possibly undetectable levels. Low levels of oxy-ferrous in the
samples may also explain the lack of accumulation of these intermediates to detectable
levels. Noting that no ferrous form of the enzyme was detected following addition of
oxygenated buffer (see Figures 2.3.12-2.3.15) during preparation of dioxygen adducts, it
may be possible that the ferric form accumulated due to autooxidation. Further RR
investigation of irradiated samples in the high-frequency region showed high content of
the ferrous form, presumably arising from radiolytic reduction of the ferric form, which
accumulated during oxy-ferrous preparation by autooxidation (Figure 2.3.24)
In an earlier study,105 Denisov et al. utilized EPR spectroscopy to characterize the
intermediates produced following radiolytic reduction of the oxy-ferrous complex of
substrate-free CYP119. The authors observed a species with an EPR signature
characteristic of the hydroperoxo intermediate (g-values = 2.29, 2.20, 1.95), which
decays to the low-spin ferric form, via a ‘peroxide shunt’ pathway, upon gradual
annealing at 170-195 K.105 Interestingly, when EPR spectroscopy was employed in the
investigation of irradiated samples of the dioxygen adducts of LA- and PFDA-bound
CYP119 (Figure 2.3.25), the respective spectra exhibited rhombic features (g = 2.28,
2.16, 1.95) characteristic of the hydroperoxo intermediate of P450s.20,30,105 Unfortunately,
a high content of the low-spin ferric form was also observed with g-values [2.40, 2.24,
1.916], possibly formed during oxy-ferrous preparation, by autooxidation, as mentioned
above. As can be seen in the EPR spectra (Figure 2.3.25 top trace) at 77 K, the low spin
ferric content is higher in the PFDA-bound CYP119 samples; this may be attributed to
the lower binding affinity of PFDA as compared to LA, such that autooxidation is
possibly faster for the corresponding dioxygen adduct. Based on the EPR data, discussed
above, it can be confirmed that input of one electron into the oxygenated intermediate
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resulted in the formation of the hydroperoxo intermediate, however, to levels not
detectable by RR at 77 K inasmuch as the only scattered light collected, is from the
surface of the frozen samples. Annealing of the irradiated samples of LA- and PFDAbound CYP119 oxy-ferrous complexes resulted in the attenuation of the hydroperoxo
signal (Figures 2.3.26 and 2.3.27), as previously observed in the substrate-free
samples,105 however, both tubes reportedly broke during annealing, which explains the
low S/N ratio in the spectra from 183-198 K. Interestingly, the hydroperoxo signal for the
LA-bound sample is still present at 198 K, consistent with the higher initial content of
oxygenated LA sample compared to the PFDA-bound sample as discussed above. Noting
that these EPR studies were performed at 15 K, it may be possible that the signal of the
compound I form of CYP119 could not be detected due to fast relaxation at this
temperature.123 Rittle and Green,85 who utilized m-CPBA to artificially produce the
compound I form of CYP119, were able to detect the EPR signals consistent with an
S = 1 Fe(IV)=O that is exchange coupled with an S = ½ ligand based radical at 7.5 K.
The authors utilized high microwave power to fully saturate signals from contaminating
paramagnetic species and obtained the CYP119 compound I spectrum by difference. In
any case, the detection of the hydroperoxo intermediate, in this present work, is
especially encouraging in that there is a reasonable probability of trapping and
spectroscopically characterizing the compound I by EPR at 7.5 K, using the approach
outlined by Rittle and Green85 and possibly even by RR, provided sufficiently
oxygenated ferrous forms of substrate bound CYP119 can be produced.
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Figure 2.3.20 RR spectra of irradiated dioxygen adducts of LA-bound CYP119 in H2O
buffer [16O2 (H2O) and 18O2 (H2O)] collected using the 442 excitation line at 77 K. The
top trace shows the difference spectra of 16O2 – 18O2.
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Figure 2.3.21 RR spectra of irradiated dioxygen adducts of LA-bound CYP119 in D2O
buffer [16O2 (D2O) and 18O2 (D2O)] collected using the 442 excitation line at 77 K. The
top trace shows the difference spectra of 16O2 – 18O2.
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Figure 2.3.22 RR spectra of irradiated dioxygen adducts of PFDA-bound CYP119 in
H2O buffer [16O2 (H2O) and 18O2 (H2O)] collected using the 442 excitation line at 77 K.
The top trace shows the difference spectra of 16O2 – 18O2.
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Figure 2.3.23 RR spectra of irradiated dioxygen adducts of PFDA-bound CYP119 in
D2O buffer [16O2 (D2O) and 18O2 (D2O)] collected using the 442 excitation line at 77 K.
The top trace shows the difference spectra of 16O2 – 18O2.
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Figure 2.3.24 High-frequency RR spectra of irradiated ferric (top trace) and 18O2 (bottom
trace) complex of PFDA-bound CYP119 in D2O buffer
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Figure 2.3.25 EPR spectra of irradiated oxy-ferrous samples of PFDA-(top trace) and
LA-bound (bottom trace) CYP119 at 77 K. The strong signal at g = 2 not shown
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Figure 2.3.26 EPR spectra of irradiated samples of the dioxygen adduct of LA-bound
CYP119 at different annealing temperatures. The strong signal at g = 2 is not shown
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Figure 2.3.27 EPR spectra of irradiated samples of the dioxygen adduct of PFDA-bound
CYP119 at different annealing temperatures. The strong signal at g = 2 is not shown
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2.4 Summary
The present work employed PFDA as an inert substrate of the thermophilic
CYP119 in an attempt to generate, capture and spectroscopically characterize the
compound I intermediate. CYP119 was shown, by absorption and RR spectroscopic
methods, to bind LA and PFDA, inducing significant spin state changes at elevated
temperatures (70 °C). However, no substantial substrate-binding associated shifts were
observed in the (Fe−CO) for both substrates, possibly due to the open active site
conformation of the thermophilic enzyme. Dioxygen adducts of substrate-bound samples
of CYP119 were prepared at -20 °C, by rapidly mixing oxygen-saturated buffer with the
ferrous form of the enzyme. Formation of the oxy-ferrous complex was confirmed by RR
at 77 K where isotopic sensitive modes, consistent with the O−O bond stretching
frequency, were observed. Cryoradiolysis was employed to generate the subsequent
intermediates in the P450 catalytic cycle, specifically, the peroxo or hydroperoxo
intermediates. RR investigation of the irradiated samples at 77 K, however, could not
detect isotope sensitive bands in the regions expected for either peroxo/hydroperoxo
intermediates. Residual oxy-ferrous form was observed in the 18O2 samples of LA-bound,
possibly indicating inefficient reduction. On the other hand, EPR spectroscopy of
irradiated samples confirmed generation of the hydroperoxo intermediate (g = 2.28, 2.16,
1.95), however with a high content of the low-spin ferric form, possibly due to
autooxidation (during oxy-ferrous preparation). The hydroperoxo species EPR signal was
observed to decrease during stepwise warming from 77 to 198 K, however, tubes broke
during annealing, making interpretation of the data difficult. Noting that the high content
of the ferric low spin form in the irradiate samples could be due to autooxidation,
production of sufficiently oxygenated ferrous substrate-bound CYP119 could be achieved
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by reducing the mixing time (from 10 s to 5 s, for example) following addition of the
oxygenated buffer. In addition, autooxidation may be decreased by reducing the cooling
temperature from – 20 to – 30 ° C. This will however require increasing the glycerol
content in the buffer. On the other hand, cryosolvents mixtures such a mixture of buffered
ethylene glycol (20 %), methoxyethanol (70 %) could be employed to obtain less viscous
protein solutions at – 50 °C.124 Detection of the hydroperoxo intermediate by EPR at 15
K provides proof of reduction of the dioxygen adduct. Inasmuch as EPR detection of the
artificially produced compound I was achieved at temperatures below 8 K, performing
the above experiments at 7.5 K with irradiated samples containing an initial high content
of the oxy-ferrous form, may possibly lead to the detection of the compound I form of
CYP119 in complex to PFDA under turnover conditions for the first time.
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CHAPTER 3 NMR DERIVED PARAMETERS FOR DOCKING SUBSTRATES
TO CYTOCHROMES P450

3.1 Introduction
Cytochrome P450 2D6 (CYP2D6) is an enzyme responsible for metabolizing at
least 20% of all drugs in the market, trailing behind only CYP3A4, which metabolizes at
least 50%. The rather promiscuous behavior of these important drug metabolizing
proteins is physiologically efficient in that it eliminates the need for the body to produce
specific enzymes for each of the multitudinous pharmaceutical products or other
xenobiotic compounds encountered and is attributed to the malleability of their active
sites, which allows binding of different substrates (Table 3.1.1).125–127
Table 3.1.1 List of CYP2D6 substrates127
Amitriptyline
Amoxapine
Aripiprazole
Atomoxetine
Betaxolol
Captopril
Carvedilol
Chloroquine
Chlorpromazine
Clomipramine
Codeine
Desipramine
Dextroamphetamine
Dextromethorphan
Dihydrocodeine

Doxepin
Doxorubicin
Duloxetine
Flecainide
Fluoxetine
Fluphenazine
Fluvoxamine
Haloperidol
Hydrocodone
Imipramine
Labetalol
Lidocaine
Lomustine
Maprotiline
Methamphetamine

Methylphenidate
Metoprolol
Mexiletine
Mirtazapine
Moclobemide
Nefazodone
Nortriptyline
Oxycodone
Paroxetine
Perphenazine
Pindolol
Pipotiazine
Procainamide
Promethazine
Propafenone

Propranolol
Protriptyline
Risperidone
Sertraline
Tamoxifen
Tamsulosin
Thioridazine
Timolol
Tolterodine
Tramadol
Trimipramine
Venlafaxine
Zuclopenthixol

The presence of a basic nitrogen and a planar aromatic ring is a structural feature
common to all known CYP2D6 substrates, as shown below in some representative
structures (Figure 3.1.1).128,129
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Figure 3.1.1 Four representative structures of CYP2D6 substrates with the typical basic
nitrogen and a planar aromatic ring
Unfortunately, efficient and accurate prediction of protein-ligand interactions by
computational docking methods,130,131 which are routinely employed in determining the
relative binding affinities of potential substrates and inhibitors, is compromised by the
inherent flexibility of these binding sites. This, coupled to the fact that few crystal
structures of protein-ligand complexes exist for these mammalian P450s, highlights the
need for the development of strategies that can furnish valuable experimentally derived
parameters for application in docking routines.
Another long time problem of studying mammalian membrane bound P450s is the
difficulty in expression and their lack of solubility in aqueous buffers such that the use of
detergents is required to solubilize the proteins. In recent years soluble forms of
mammalian proteins have been heterologously expressed in E. coli strains transformed
with plasmid constructs bearing truncated P450 gene fragments that lack the N-terminus
(hydrophobic membrane spanning) region.128,132 Rowland et al 128reported the crystal
structure of a ligand-free (Figure 3.1.2) truncated form of the human CYP2D6 in which
the N terminus of the wild type protein had been truncated at residue 34 and replaced
with a more hydrophilic 2C3d N –terminus (residue 2-10). In order to increase the
solubility, site directed mutagenesis was used to replace leucine surface hydrophobic
residues at position 230 and 231 with the more hydrophilic aspartate and arginine
residues, respectively. 128
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Figure 3.1.2 The crystal structure of ligand-free CYP2D6128

The ligand-free structure reported by Rowland et al differs significantly from the recently
published structure of prinomastat (a substrate and potent inhibitor of CYP2D6) bound
CYP2D6 (Figure 3.1.3).132 Differences were evident in  sheet 1, helices A, F, F`, G”, G
and H as well as the helix B-C loop. Prinomastat bound CYP2D6 exhibits a closed cavity
active site, which closely conforms to the substrate structure as compared to a rather open
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active site of the ligand-free enzyme. This apparent induced fit model was attributed to a
change in the direction and pitch of helix F and a turn at Gly-218, which is followed by a
well defined helix F` not observed in the ligand-free structure (Figure 3.1.3).132

Figure 3.1.3 Superposition of the prinomastat-bound (cyan) and ligand-free (light
magenta) crystal structures. The arrow indicates the F’ helix present in the substrate
bound structure.132
Inasmuch as the number of crystal structures of protein-ligand complexes is likely
to increase with the advent of better methods to express soluble mammalian proteins,
adequate representation of the flexible P450s active sites could still be a challenge. Thus
the potentially tremendous value of solution structure determination by spectroscopic
methods cannot be over emphasized. The present study aims at exploiting NMR
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spectroscopic methods to define the solution active site architecture of P450s. Thus,
NMR measurements of P450s bearing isotopically labeled heme will be used to derive
distances between reference points on the heme prosthetic group and substrate protons.
Isotopically labeled P450cam was employed as a proof of principle exercise for this
strategy of defining active site structure in mammalian P450s using NMR methods. More
specifically, P450cam containing a heme group 13C-labeled at the methine carbons was
heterologously expressed in E-coli cells grown on media supplemented with [5-13C] aminolevulinic acid ([5-13C] -ALA, a precursor in the heme biosynthesis). It is noted
that use of this particular labeled precursor results in labeling of C and Cm carbons on
the heme group (Figure 3.1.4), the latter of which will be useful for application of the
nuclear Overhauser effect (NOE), an NMR technique used to determine spatial proximity
between nuclei. NOEs will be measured for the methine protons (using 13C filter),
providing needed data to determine relative distances from detectable substrate and active
site amino acid residues protons. This will provide better definitions of substrate
disposition in the active site and offer experimentally derived parameters, which are of
potential value in docking calculations involving drug metabolizing enzymes.
Incorporation of spectroscopically derived restrictions in docking routines will further
refine these computational methods of defining the relative binding affinity and
disposition of substrates in the active site of the protein
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Figure 3.1.4 Supplementing bacterial media with [5-13C] -ALA will result in the
biosynthesis of heme labeled at the Cm and Cα positions; black dots mark the positions of
13
C enrichment79
3.2 Materials and Methods
The HU227strain of E.coli cells were kindly provided by Professor Gregory M.
Raner of University of North Carolina Greensboro. CYP101 plasmids were isolated from
E. coli BL21 cells using the Zippy plasmid prep kit (Zymo Research Corporation). The
CYP2D6 construct was custom designed and synthesized by GenSript and cloned into
pUC57. Subcloning of the CYP2D6 gene into the pCWori (from the CYP101 construct
provided by Professor Paul R. Ortiz de Montellano of the University of California San
Francisco) was also performed by GenSript. Phthalic anhydride and NaI were purchased
from Sigma Aldrich while ethyl 3-bromopropionate, Zn-Cu couple and Pd(PPh3)4 were
purchased from Alfa Aesar and used without further purification. The isotopically labeled
[2-13C] glycine was purchased from Cambridge Isotope Laboratories.
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3.2.1 Synthesis of [5-13C] -Aminolevulinic acid (ALA)
Synthesis of [5-13C] -ALA with an average yield of 70% was achieved in four
steps (Scheme 3.2.1) from [2-13C] glycine following published procedures, with minor
modifications.94,95 Specific details of the procedure summarized are for the natural
abundance -ALA. The 13C enriched heme biosynthesis precursor was synthesized from
[2-13C] glycine after successful optimization of the procedure.

Scheme 3.2.1 Synthesis of [5-13C] -ALA, the asterisk represents the 13C enriched carbon
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Step 1: Synthesis of N-phthalimido acetic acid
Well ground phthalic anhydride (~2 g, 13 mmol) and ~1 g (13 mmol) of natural
abundance glycine were weighed and transferred to a 50 mL round bottom flask. The
solids were mixed well before heating at ~180°C until the whole was melted (~ 5 min).
This was followed by rigorous stirring for another 5 min, after which the mixture was
cooled to give a yellow residue. The residue was dissolved in ~ 20 mL of hot water
(~ 80°C) and left to recrystallize for about 2 h, after which needle-like transparent
crystals had formed. The crystals were filtrated and allowed to dry in a desiccator
containing P2O5. The procedure was repeated using [2-13C] glycine to produce Nphthalimido [2-13C] acetic acid. The 1H- NMR of the recrystallized product matched the
published spectra of N-phthalimido acetic acid.94
Synthesis of Ethyl 3-iodopropionate
About 17 g (~110 mmol) of NaI were transferred to a 250 mL flame dried 2-neck
round bottom flask, to which was added 10 mL (78 mmol) of ethyl 3-bromopropionate
and 100 mL of 2-butanone. The flask was purged with argon for about 10 minutes and
then refluxed at 90 °C for 16 h under argon. After cooling the suspension was filtered,
giving a reddish brown filtrate and a yellowish-white solid. The filtrate was evaporated
using the rotary evaporator to remove 2-butanone, after which it was diluted with
~ 80 mL of diethyl ether. This organic solution was washed with brine (3 x ~50 mL
washings), followed by distillation to give ethyl 3-iodoprionate in 61% yield.
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Step 2: Phthalimido acetyl chloride
A 2.3 g (11 mmol) portion of natural abundance N-phthalimido acetic acid was
weighed and transferred to a flame-dried 50 mL round bottom flask, to which 30 mL of
SOCl2 was added. The mixture was refluxed at 80°C for 18 h after which the reaction
was cooled and the excess SOCl2 was removed by rotary evaporator. The residue was
dissolved in 5 mL of dry toluene and evaporated (this was done 3 times) to remove
excess SOCl2. Immediately before use in the coupling reaction, described below, the
product was dissolved in 5 mL of anhydrous toluene under Ar.
Step 3: Ethyl phthalimido levulinate
A 1.0 g portion of Zn-Cu couple was weighed and transferred to a flame-dried 2neck 50 mL round bottom flask. The flask was flushed with argon for 10 minutes
followed by addition of dry toluene (1.2 mL) and 14 mL of N,N-dimethylacetamide
(containing < 1% H2O) under argon. Ethyl 3-iodopropionate (2.0 mL, 12.4 mmol) was
added to this suspension and the mixture was stirred for 15 h at 60°C followed by
addition of a suspension of Pd(PPh3)4 (~530 mg) in 5 mL of dry toluene under argon. The
reaction flask was then stirred for 5 min at 60°C followed by the addition of a 5 mL of a
suspension of partially dissolved phthalimido acetyl chloride in dry toluene. The reaction
was stirred for an additional 25 min and then diluted with 300 ml ethyl acetate. This
mixture was washed with 1 N HCl (250 mL), saturated NaHCO3 (250 mL) and brine (250
mL), dried over MgSO4, filtered and evaporated. The resulting reddish-brown residue
containing the desired product, as judged by 1H NMR,94 was passed through a silica gel
(60) column (15″ x 1.8″) using ethyl acetate: hexane (1: 1) solvent system. The fractions

92
were checked by TLC; those with a single spot were pooled and the presence of the
desired product verified by 1H NMR and melting point measurements (vide infra).

Step: 4 Aminolevulinic acid (ALA)
A 480 mg (1.60 mmol) portion of ethyl phthalimido levulinate was transferred to
a 25 mL round bottom flask followed by addition of ~ 6 mL of 6 N HCl. The mixture was
refluxed at 110 °C for ~24 h. After cooling to room temperature, the reaction mixture was
filtered (crystals of phthalic acid, ~180 mg) and the resulting aqueous filtrate was washed
3 times with diethyl ether (10 mL). The aqueous filtrate was evaporated giving a brown
residue, which was recrystallized from an ethanol-ether solution (3 mL). This procedure
was repeated using ethyl 5-N phthalimido [5-13C] levulinate to yield [5-13C] -ALA in
~ 70% yield.

3.2.2 Expression of [5-13C] -ALA P450cam
Viability of HU227 E-coli cells
The cells of the -ALA synthase-deficient E-coli strain, HU227 obtained as a gift
from Dr. Raner (University of North Carolina Greensboro) require CaCl2 treatment133 to
render them competent prior to transformation with the P450cam gene. The viability of
the cells was tested by aseptically growing them overnight on LB plates supplemented
with the natural abundance -ALA. After 12 h of incubation at 37 °C, several colonies
appeared in LB plates supplemented with 20 mg/L -ALA whilst no growth was
observed in plates without -ALA (negative control plates). Single colonies were picked

93
to inoculate 50 mL of LB medium containing 20 mg/L ALA. The cells were shaken (250
rpm) at 37 °C until an OD600 of 0.5 (~3 h). The cells were diluted further by spreading 10
µL on LB plates supplemented with ALA and grown overnight at 37 °C. Single colonies
were picked and the process repeated as described above. Plates with well separated
colonies were stored at 4 °C prior to preparation of competent cells.
Preparation of Competent cells
A single colony of HU227 cells was picked and used to inoculate 100 mL LB
medium containing 20 mg/L ALA. The cells were grown (at 225 rpm and 37 °C) to an
OD600 of 0.5. Ideally for normal E. coli strain, cells should reach an OD600 of 0.5 after 3h
of vigorous shaking; however the cultures in this work reached an OD600 of less than 0.1
after ~5h of incubation, possibly indicating high level of cell deaths of this fragile strain
of E. coli. The cells were left at 4 °C overnight and then transferred to the shaking
incubator at 37 °C, finally reaching an OD600 of 0.5 after about 2 h. The cells were
transferred to ice cold 50 mL polypropylene tubes and incubated on ice for about 10
minutes. The cells were recovered by centrifugation at 4100 rpm for 10 min and the
medium decanted. The tubes were inverted on a wad of paper towel to drain away all
traces of media. Each pellet was resuspended in 30 mL of ice-cold MgCl2-CaCl2 solution
(80 mM Mg Cl2, 20 mM CaCl2) and mixed by gently swirling. The cells were recovered
again by centrifuging at 4100 rpm for 10 minutes followed by decantation of the medium.
All traces of the media were drained away by inverting the tubes on a wad of paper towel
for about a minute. Each pellet from the original 50 mL culture was resuspended by
gently swirling in 2 mL of ice-cold 0.1M CaCl2. Frozen stocks of HU227 competent cells
were prepared by gently mixing each 2mL suspension with 70 µL of DMSO and
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incubating on ice for 15 min followed by an additional 70 µL of DMSO. Aliquots of
50 µL were transferred to pre-chilled microcentrifuge tubes using sterile chilled pipette
tips and immediately frozen using liquid nitrogen. Cells were stored at -80 °C overnight
prior to transformation as described below.
Transformation of HU227 cells and expression P450cam
The CaCl2 treated HU227 competent cells were transformed with the pCWori
plasmid harboring the P450cam gene and selected for ampicillin resistance on LuriaBertani (LB) agar plates supplemented with -ALA (20 mg/L). A single colony was
utilized to initiate expression of P450cam. Specifically, transformed HU227cells were
grown (from a single colony) overnight at 37 °C in 10 mL LB broth supplemented with
ampicillin and -ALA (20 mg/L). About 1% of the overnight culture was used as
inoculum in 100 mL of 2YT medium (16 g tryptone, 10 g yeast extract and 5 g NaCl per
1L) also supplemented with ampicillin and -ALA. The cells were grown to OD600 = 0.8
at 37 °C and 250 rpm followed by addition of 1 mM isopropyl -D-1thiogalactopyranoside (IPTG) and 0.5 mM -ALA. Induction was allowed to proceed for
24 h at room temperature and shaking at 190 rpm. After 22 h of induction, solid camphor
was added to the culture to a final of concentration of 1 mM. The cells were harvested
after 24 h of induction by centrifugation at 8000 rpm for 10 min, weighed (12 g/L of
culture) and frozen at -80°C. Cells were thawed, resuspended in 3 volumes (3 mL/g of
wet cells) of lysis buffer [50 mM Tris-Cl (pH 7.4), 25 mM KCl, 1 mM PMSF, 1 mM
camphor, 1 mM EDTA, 1 mg/mL lysozyme, 1 g/mL leupeptin, 1 mg/mL pepstatin,
1 mg/mL antipain, 32 Units/mL DNase I, 3 Units/mL RNase A)] and incubated at 4 °C
for 30 min followed by sonication. Cells were centrifuged at 20 000 rpm for 2 h and the
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clarified lysate was concentrated to about 5 mL and loaded onto an anion exchange
(DEAE-cellulose) column (3 x 15 cm) equilibrated with 50 mM Tris-HCl (pH 7.4), 25
mM KCl, 1 mM camphor (running buffer). The bound protein band was washed with 6
column volumes (CVs) of the running buffer and eluted by a linear gradient using 50 mM
Tris-HCl (pH 7.4), 300 mM KCl, and 1 mM camphor as the elution buffer. Fractions with
an Rz (A391/A280) > 0.5 were pooled and concentrated (to about 5 mL) followed by
addition of ammonium sulfate (75 mg/mL) The pooled fractions were loaded onto a
hydrophobic interaction (Phenyl Sepharose) column equilibrated with 50 mM Tris-HCl
(pH 7.4), 25 mM KCl, 1 mM camphor, 25% (NH4)2SO4 and washed with 6 CVs of the
same buffer. The elution buffer contained 50 mM Tris-HCl (pH 7.4), 25 mM KCl
and1 mM camphor. Elution of the bound protein was achieved by applying a linear salt
gradient 25-0% (NH4)2SO4 and fractions exhibiting Rz > 1.4 were pooled and
concentrated to about 2 mL. Ammonium sulfate was removed by exchanging the buffer
to 30 mM KPi (pH 7.4), 100 mM KCl, 1 mM camphor D2O using microsep centrifugal
devices. Equilibration of samples in D2O buffer was performed as an initial step for
preparing samples for NMR measurements. When expression was scaled up to 1 liter of
2YT medium, 0.3 mL of ~ 0.4 mM pure P450cam (Rz = 1.5) was obtained. Protein
concentration was calculated from the absorption spectra, using an extinction coefficient
of 391 = 102 mM-1cm-1 for the camphor bound CYP101.134 The preceding procedure was
repeated using [5-13C] -ALA resulting in the expression of 13C-labeled P450cam (0.5
mL of ~ 0.2 mM, Rz 1.5; Figure 3.2.1).
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Figure 3.2.1 The absorption spectrum of high spin ferric cytochrome P450cam

3.2.3 CYP2D6 expression
Rowland et al (2006)128 described modifications for the CYP2D6 construct,
which included N-terminus truncation (truncated at residue 34 and residues 2-10 of 2C3d
inserted at the N terminus), addition of 4 histidines at the C-terminus and mutations of the
hydrophobic residues at positions 230 and 231. They reported high level expression of
soluble holo-CYP2D6 using this truncate (truncate 5) in E. coli (DH10B strain).128 These
modifications described above were used to design a replica of truncate 5 using the wild
type gene sequence (NCBI Gene bank: ADF36476.1). Codons for the modifications were
derived from reverse translation of the amino acid sequence of 2C3d (for the N terminus)
and L230D/L231R mutations and optimized for the E.coli expression system (see Figure
3.2.2 for the gene and protein sequences below). NdeI and XbaI restriction endonuclease
recognition sites where introduced at the N and C termini respectively to allow subloning
into the pCWori+ expression vector.
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Figure 3.2.2 The gene (top) and protein (bottom) sequences of truncated CYP2D6

The construct was commercially synthesized (by GenSrcipt) and delivered as a
lyophilized pUC57 plasmid. The gene was subcloned into pCWori (also by GenSript) and
transformed into BL21 and competent HU227 cells for production of the natural
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abundance and [5-13C] -ALA labeled CYP2D6 respectively. The detailed expression
procedure is outlined below. This procedure (with slight variations) has been used to
successfully produce [5-13C] -ALA CYP101 as already discussed earlier.
Transformed BL21cells were grown (from a single colony) overnight at 37 °C in 10
mL LB broth supplemented with 100 mg/L ampicillin. 1% of the overnight culture was
used as inoculum in 100 mL of TB medium [(12 g tryptone, 24 g yeast, 9.4 g K2PO4, 2.2
g KHPO4, 4 mL glycerol)/L] supplemented with ampicillin (100 mg/L), 20 mg/L ALA, 1 mM thiamine and trace elements [(27 g FeCl3.6H2O, 2 g ZnCl2.4H2O, 2 g
CoCl2.6H2O, 2 g Na2MoO4.2H2O, 2 g CaCl2.2H2O, 1 g CuCl2, 0.5 g H3BO3, 100 mL HCl
conc)/L] solution (3 mL per liter of culture).135 The cells were grown at 30 °C with
shaking at 250 rpm to an OD600 = 0.6, followed by addition of 1 mM IPTG. Induction
was allowed to proceed for 24 h at room temperature and shaking at 190 rpm. The cells
were harvested by centrifugation at 8000 rpm for 10 min, weighed (12 g/L of culture) and
frozen at − 80°C. Expression of CYP2D6 was checked by CO difference spectra of the
total cell lysate. Briefly, cells (~ 1 g) were freeze-thawed twice and resuspended in 4 mL
of 400 mM KPi buffer (pH 7.6), 20 % glycerol, and 1 mM CHAPS. The lysate (~ 4 mL)
was clarified by centrifugation at 20 000 rpm for 10 min. The clarified solution (~ 3 mL)
was transferred to a gas tight 10 mm cuvette, bubbled with CO gas for ~ 20 min and
treated with excess Na2S2O4 (10 L of 50 mM dithionite solution). The absorption
spectrum was collected using the Hewlett-Packard Model 8452 Diode Array
Spectrophotometer. The supernatant, presumably containing the cytosolic fraction of the
truncated CYP2D6, was obtained following cell lysis performed according to a published
procedure.128 The cytosolic fraction in 400 mM KPi, pH 7.4, 20% glycerol and 10 mM mercaptoethanol buffer, was loaded onto a Ni2+-nitrilotriacetic acid column equilibrated
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with the same buffer and washed with 6 CVs washing buffer containing 400 mM KPi, pH
7.4, 20% glycerol, 10 mM -mercaptoethanol, 50 mM glycine and 100 mM NaCl. The
bound fraction was eluted using a linear gradient 0-100 mM EDTA (and simultaneously
glycine concentration of 50 to 0 mM) of elution buffer (400 mM KPi, pH 7.4, 20%
glycerol, 10 mM -mercaptoethanol, 100 mM EDTA), as previously reported.128
Fractions exhibiting spectral characteristics of CYP2D6 (Soret band at 415 nm) were
pooled, concentrated and checked for P450 (and any P420) by CO difference spectra. The
procedure described above was scaled up and applied to BL21 cells transformed with the
pCWori+ plasmid bearing the truncated gene of CYP2D6.

3.2.4 Resonance Raman Spectroscopy of [5-13C] -ALA P450cam
RR measurements of ferric forms of the natural abundance and 13C enriched
P450cam were essentially the same as described earlier except that the 406 nm excitation
line from the Kr+ laser (Coherent Sabre) was used with ~ 15 mW at the sample and that
spectra were collected at room temperature.

3.2.5 NMR spectroscopy
1

H and 1H-13C heteronuclear single/multiple-quantum correlation (HSQC/HMQC)

NMR measurements were performed using Varian 600 MHz equipped with a tripleresonance cryoprobe while 1 D 13C NMR experiments were done on the Varian 400 MHz
instrument. NMR samples contained ~0.4-1 mM P450cam (both for the natural isotopic
abundance and 13C enriched camphor bound P450cam), 30 mM KPi, pD 7.4, 100 mM
KCl, 1 mM camphor. The protein concentration was determined spectrophotometrically
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using an extinction coefficient of =102 mM-1cm-1 for the camphor bound P450cam.136
Substrate free samples were prepared by passing the camphor bound protein through a
sephadex G25 column equilibrated with 50 mM MOPS buffer followed by equilibration
with 30 mM KPi, pD 7.4, 100 mM KCl. One dimensional 1H NMR experiments were
performed using 0.1 s acquisition time, 20 ms relaxation delay with a total of 256 scans at
25 °C and were collected before and after 13C and 2 D NMR measurements to verify
sample integrity. A total of 400 000 scans were collected for the 13C NMR experiment at
20 °C for both the natural abundance and 13C enriched substrate bound P450cam. The 1 D
version of 1H-13C HSQC measurements for the natural abundance and 13C enriched
substrate bound and free P450cam were performed at 20 °C using 23 ms acquisition time,
0.2 s relaxation delay and JCH = 200 Hz; a total of 240 000 scans were collected. 1H-13C
HMQC experiments, with the decoupler turned off, were performed using 50 ms
acquisition time, 10 ms relaxation delay and JCH = 300. 1H-1H NOESY was obtained with
pre-saturation delay of 100 ms, acquisition time of 43 ms, 10 ms mixing time, JCH = 600
and 7200 number of scans. All 1D NMR data were processed with the MestReNova
NMR processing software with 10 Hz exponential line broadening while 2D spectra were
processed using the NMRPipe software.
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3.3 Results and Discussion
3.3.1 Synthesis of [5-13] -ALA
Step 1: Synthesis of N-phthalimido acetic acid
The first step in the synthesis of ALA was relatively straightforward and complete
in 5 min giving pure (see 1H NMR in Figure 3.3.1) N-phthalimido acetic acid in ~86%
yield (~2.3 g, 11.2 mmol) with a melting point between 192-197 °C (reported mp is
between 193-195 °C)94 after recrystallization from hot water

Figure 3.3.1 1H NMR of natural abundance (B) and 13C enriched (A) N-phthalimido
acetic acid dissolved in CDCl3
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Synthesis of Ethyl 3-iodopropionate
Distillation of the reaction mixture of NaI and 3-bromopropionate (in
2-butanone), after refluxing for 16 h at 90 °C, resulted in 61% yield (10.93 g) of
3-iodopropionate. The 1H NMR (Figure Figure 3.3.2) shows a slight down-shift of the
proton signals (a) located on C3 that is directly bonded to the halogen, indicating the
success of the transhalogenation reaction.

Figure 3.3.2 1H NMR of ethyl 3-bromopropionate (A) and ethyl 3-iodopropionate (B) in
CDCl3
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Step 2: Phthalimido acetyl chloride
(a) Initial attempts
Initial attempts to synthesize phthalimido acetyl chloride following the methods
of Kajiwara and Iida94, resulted in a product that dissolved partially in anhydrous
toluene, which was used to remove traces of SOCl2. Removal of the solvent resulted in a
dirty-yellowish-white solid. Noting that, in addition to the desired product, acetyl
chloride, gaseous SO2 and HCl are produced in this reflux, these may possibly react with
rubber septa (the reaction was initially set up as a closed system under Ar) resulting in the
dirty yellowish-white color observed. When an open system was used, the residue
obtained after removal of SOCl2 dissolved in dry toluene and was yellowish-white in
color. The average yield from the three trials performed on this reaction was ~ 95 %
(2.1 g, 2.2 g, 2.2 g) and the purity improved on the third trial as judged by 1H NMR and
melting point measurements. The product was left to dry in a desiccator containing P2O5.
The acetyl chloride was flushed with argon for ~ 10 min and dissolved in 5 mL (the
dissolution was only partial) dry toluene immediately before being coupled with
2-ethoxycarbonylethylzinc iodide as described in the following section (Step 3). It was
noted (by 1H and 13C NMR, Figure 3.3.3) after failed repeated attempts to dissolve
phthalimido acetyl chloride (obtained after refluxing phthalimido acetic acid and SOCl2
at 80 °C for 18 h94), that when left for ~3 days contained about 25% phthalimido acetic
acid, which suggests it is not stable. Phthalimido acetic acid is not soluble in toluene,
which may explain the partial solubility mentioned above.
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(b) Revised procedure for the synthesis of phthalimido acetyl chloride
This same reaction was reported by Deng et al., 2008137 to be complete in about 3
h at a lower temperature of 60 °C, followed by removal of excess SOCl2 at 55 °C (~ 70
°C was used in the reactions described above). They found that the product was partially
decomposed at higher temperatures, which might explain the lower yields obtained in the
coupling reactions (vide infra). In addition, they pointed out the need to use the product
immediately after dissolution in an anhydrous solvent.147 When this procedure (of Deng
et al)137 was followed (10 mlL of SOCl2 was used in the reflux), the reaction was
incomplete after 3 h as judged by 1H NMR. It was noted that the reaction is almost done
after 2 h when heated to 75 °C and complete after 3 h. Removal of the excess SOCl2 was
done under reduced pressure at ~ 55 °C. The resulting yellow crystalline product was
dissolved in 3 mL of dry toluene and evaporated (done twice). A few mg of the product
was dissolved in CDCl3 for 1H & 13C NMR measurements and the rest of the sample was
left to dry in a desiccator overnight to check its stability. The product was found to be
stable overnight (by 1H and 13C NMR, see Figure 3.3.4), giving enough time to couple
with the 2-ethoxycarbonylethylzinc iodide reaction, which runs overnight for 15 h.
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Figure 3.3.3 The 1H NMR spectra of a mixture of phthalimido acetyl chloride and its
acid derivative (x; ~ 25% of phthalimido acetic acid). The inset shows the extra 13C
signal (x) from the acid derivative
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Figure 3.3.4 The 1H NMR of natural abundance (top trace) and 13C enriched (bottom
trace) pure phthalimido acetyl chloride (in CDCl3) after 3 h of refluxing phthalimido
acetic acid and SOCl2. Inset shows the 13C NMR spectra of the natural abundance
phthalimido acetyl chloride
Step 3: Ethyl phthalimido levulinate
(a) Initial attempts
1

H NMR of the chromatographed product of the coupling reaction of N-

phthalimido acetyl chloride and 2-ethoxycarbonylethylzinc iodide exhibited chemical
shifts of the desired product, ethyl phthalimido levulinate; however, very low yields were
obtained. Verification of desired product in chromtographed fractions was also done by
absorption spectroscopy, whereby the spectrum of the ethyl phthalimido containing
fractions (judged by 1H NMR and reported mp)94 had a maximum at ~ 290 nm (Figure
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3.3.5), The low yields obtained could be attributed to the partially dissolved phthalimido
acetyl chloride, which as explained above is not stable and easily reverts to the acid form.
The use of completely dry solvents and oxygen free atmosphere was discovered to be
crucial for obtaining better product yields. Improved yields of up to 800 mg (~25%) were
obtained when the coupling reaction was done in a glove box, but still employing
partially dissolved phthalimido acetyl chloride. This was however still very low
compared to the 92% reported by Kajiwara and Iida (2002).94 Campbell and Johnston
(1989)95 in their synthesis of 5-amino [4-14C] levulinic acid, reported this coupling
reaction as the key step. They used 200 mL of ethyl acetate to dilute the reaction mixture
and used only 50 mL in their washings. In the present work the lower yields obtained
could possibly be due to loss during the washings therefore smaller volumes of the
aqueous washes were adopted in the modified procedure briefly described below.
(b) Improved procedure
Ethyl 3-iodopropionate (~ 2.5 mL) was added to a suspension of Zn-Cu couple
(1.35 g) in ~27 mL of dry toluene and ~ 2 mL of anhydrous dimethylacetamide under
argon. The whole was stirred for 1 h at room temperature and at 60 °C for 4.5 h under Ar
instead of 15 h. To this flask was added a suspension of 418 mg Pd(PPh3)4 in 5 mL of dry
toluene under argon, followed by stirring for 5 minutes at 60 °C, after which a solution of
phthalimido acetyl chloride (~ 2 g) in 5 mL of dry toluene was added and stirring
continued for an additional 10 min; longer times (15 min >) have been reported to
produce side products, which makes it necessary for stringent purification steps to be
employed.95 The reaction was diluted with ethyl acetate (~200 mL), washed with 1 N
HCl (50 mL), saturated NaHCO3 (50 mL) and brine (50 mL), dried over anhydrous
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MgSO4 and filtered. An orange residue (crude product) was obtained; note the difference
in the color from reddish brown that was discussed earlier. Removal of solvent by rotary
evaporator followed by recrystallization from absolute ethanol (5 mL) gave white crystals
of pure ethyl phthalimido levulinate in 75% yield (average of 2 trials).

Figure 3.3.5 1H NMR of 13C enriched ethyl phthalimido levulinate dissolved in CDCl3
(s); Insert shows the absorption spectrum of fractions containing pure ethyl phthalimido
levulinate
Step: 4 Aminolevulinic acid (ALA)
Hydrolysis of ~ 480 mg of ethyl phthalimido levulinate in 6N HCl resulted in
~ 140 mg (65 %) white crystals of pure ALA after recrystallization from ethanol-ether
(Figure 3.3.6). Approximately 20 mg of the starting material, ethyl phthalimido
levulinate, was recovered following evaporation of the ether layer, indicating a

109
reasonably high conversion rate; based on the theoretical yield calculations, ~ 60 mg of
product was lost possibly during the washings (washing of the aqueous layer with diethyl
ether following filtration of the hydrolysis reaction mixture) and/or the recrystallization
step described section 3.2.1.

Figure 3.3.6 The 1H NMR spectra of the natural abundance - ALA (bottom trace) and
[5-13C] -ALA (top trace) dissolved in D2O; insert shows the 13C NMR spectrum of the
natural abundance -ALA
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3.3.2 CYP2D6 Expression
This initial trial expression of CYP2D6 from BL21 cells transformed with pUC57
bearing the truncated gene of the protein was confirmed by the CO difference spectra of
the total cell lysate (Figure 3.3.7). When the cytosolic fraction was applied onto the
Ni2+ -nitrilotriacetic acid column only a small fraction was bound and the eluted fraction
exhibited spectral characteristics consistent with a hexacoordinated heme species (top
trace of Figure 3.3.8).138,139 Upon elution with the gradient described above, the initially
bound fraction, however, exhibited an absorption maximum at around 415 nm (middle
trace of Figure 3.3.8), which is characteristic of low spin heme protein. Expression of
CYP2D6 from glycerol stocks could not be confirmed in subsequent trials; rather, an
absorption spectrum characteristic of a six coordinated heme species, which was resistant
to reduction, was observed (Figure 3.3.9). It is possible that the C-terminus histidine of
one protein molecule coordinates to the heme iron of another CYP2D6 molecule resulting
in a hexacoordinated species. Additionally, the observed optical properties of the total
cell lysate could be arising from spontaneous mutations (probably deletion during
storage) in the CYP2D6 gene from the frozen glycerol stocks used, considering the fact
that P450 expression was successful in the first trial. On the other hand, when the
expression procedure was followed by SDS electrophoresis (Figure 3.3.10), a band with a
molecular weight characteristic of the truncated CYP2D6 is present in whole cells (too
dilute), clarified lysate (supernatant), Ni2+ -bound and the flow through (FT) fraction. The
pellet obtained after clarification of the cells lysate does not have the CYP2D6 band, as
expected. When the expression was performed using freshly transformed BL21 cells
grown in 2.5 L flasks containing a maximum of 500 mL of TB media (to allow efficient
aeration), the cell lysate exhibited a Soret band around 400 nm and a shoulder at ~ 423
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nm (Figure 3.3.11, trace A). The reduced CO difference spectrum shows a maximum at
443 nm, which is ~ 5 nm lower than the expected (Figure 3.3.11, trace B-A).
Surprisingly, when the cell lysate was treated with 1 L of freshly prepared 12 mg/mL
Na2S2O4, a feature at ~ 447 nm appears after 10 minutes even before adding CO (Figure
3.3.12), possibly indicating a ferrous hexacoordinated heme. Moreover this shoulder at
447 nm diminishes with bubbling of CO. It was also noted that the pCWori+ vector
utilized in the subcloning of the truncated CYP2D6 was shown (sequencing performed by
Gensript) to exhibit a deletion beyond the XbaI site (see Figure 3.2.2), which was initially
assumed to be by design (by Ortiz de Montellano, when they constructed the P450cam
expression plasmid)140 and hence inconsequential to expression of functional protein.
However the present results may be indicating the effect of the deletion on the
expression, possibly resulting in an incorrectly folded protein. Obviously, it seems
possible that subcloning of the truncated gene of CYP2D6 into a functional pCWori+
expression vector might result in the production of functional soluble protein. Recently,
Pan, Y. et al141 have designed an expression system for the full length CYP2D6 with the
N-terminus modified to incorporate eight residues from bovine CYP17. They
demonstrated successful expression of CYP2D6 by immunoblotting and reduced CO
difference spectral scanning, obtaining holoprotein yields of 371 pmol/mg protein.
Noting that solubilization of the full length protein may require utilization of detergents;
this expressed protein may be more effectively solubilized with the nanodisc technology
elegantly developed by the Sligar group,142–144 in which an encircling amphipathic
membrane scaffold protein (MSP) capable of stabilizing a phospholipid bilayer functions
as a belt around a hydrophobic core. The advantage of this technology is that the protein
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is essentially in a native like environment, permitting better characterization by
biophysical methods.

Figure 3.3.7 The absorption spectra of clarified cell lysate containing crude CYP2D6
(red trace) and the ferrous CO difference spectra of CYP2D6

Figure 3.3.8 The absorption spectra of crude CYP2D6 (top trace), Ni2+ -NTA bound
fraction (middle trace) and the Ni2+ flow through fraction (bottom trace). The insert
(right) shows the full spectrum of the eluted bound fraction of CYP2D6
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Figure 3.3.9 The absorption spectrum of the total cell lysate (from subsequent CYP2D6
expression trials) saturated with CO and incubated in excess sodium diothionite

Figure 3.3.10 SDS-PAGE monitoring CYP2D6 expression and purification (bands
in the black rectangular box are possibly from the truncated CYP2D6). Lane 1
(marker), 2 (whole cells), 3 (cell pellet after lysis), 4 (cytosolic fraction), 5 (NiNTA column flow through fraction), 6 (Ni-NTA bound fraction), 7 (CYP2D6 from
Prof. Waskell).
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Figure 3.3.11 The UV-vis absorption spectra of CYP2D6 lysate (A), its Na2S2O4 reduced
CO form (B) and the difference spectrum of B-A

Figure 3.3.12 The absorption spectra of CYP2D6 cell lysate (A), Na2SO4 reduced forms
(B), reduced CO forms (C) and the difference spectra of B-A and C-A
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Figure 3.3.13 Part of the pCWori+ sequence in the multiple cloning site region, the
highlighted part shows the deleted bases in the P450cam construct used for subcloning
the CYP2D6 gene
3.3.3 Resonance Raman Spectroscopy of [5-13C] -ALA P450cam

The high frequency resonance Raman spectra of the natural abundance and
[5-13C] -ALA SBP450cam are shown in Figure 3.3.14. The oxidation state marker band,
4 for the natural abundance P450cam shown in the top trace (A) occurs around
1370 cm-1 as expected for the ferric form of the protein, the mode is shifted by 13 cm-1
for the isotopically enriched analogue (trace B). This is to be expected in as much as this
A1g porphyrin breathing mode contains significant contributions from the C−N
stretches42–44 four of which are 13C enriched (Figure 3.3.14 insert). Another mode of
interest, which shifts significantly upon isotopic substitution, is the so called spin state
marker band or 3, and has been previously shown to arise from C− Cm symmetrical
stretches.42 The other spin state marker band, 2 occurring at 1570 cm-1 for the natural
abundance and contains substantial contributions from the (C− C) stretching mode
only shifts slightly and appears as a broad band centered at 1568 cm-1. Normal mode
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calculations and isotopic studies of heme model compounds demonstrated mixing of the
C – C and C – Cm stretching modes although less significant for 2,42–45 it may explain
the broadening observed in the present work. Interestingly, 13C isotopic substitution
reveals the two vinyl stretching modes, which have been previously identified in
P450cam reconstituted with protoheme-d4.22
The corresponding low frequency RR spectra shows further evidence of isotopic
substitution particularly with the mode containing significant contributions from
symmetric pyrrole deformation (7) shifting down with 13 cm-1.42 Additionally, a new
feature at 412 cm-1, presumably arising from a vinyl bending mode, is activated in the 13C
enriched analogue of P450cam (Figure 3.3.15). These observations provide RR
spectroscopic evidence for the successful heterologous expression of the bacterial
P450cam bearing 13C enriched prosthetic group at the Cand Cm positions.
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Figure 3.3.14 The high frequency RR spectra of the natural abundance (A) and [5-13C] ALA (B) substrate bound P450cam acquired with the 406 nm laser excitation line at
room temperature. Insert: heme numbering, the 13C enriched carbons are marked with
black dots

Figure 3.3.15 The low frequency RR spectra of (A) and [5-13C] ALA (B) substrate bound
P450cam acquired with 406 nm laser excitation
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3.3.4 NMR spectroscopy of [5-13C] -ALA P450cam

(a) Initial attempts
NMR measurements were acquired for both the high (HS) and low spin (LS)
forms of natural abundance P450cam and its 13C-labeled analogue. Specifically, 1D 13C,
1

H and 2D 1H-13C HSQC NMR experiments were performed to identify the meso proton

resonances, which are, in this case, required in NOE measurements. The inherent long
electronic spin relaxation time of the heme iron causes very short relaxation times of the
surrounding protons resulting in large line widths of the paramagnetically shifted
resonances (Figure 3.3.16). The four hyperfine-shifted signals (A-D in Figure 3.3.16)
outside of the protein envelope have been assigned to the heme peripheral methyl
substituents.72,73,145 Narrow line widths permits utilization of NMR NOE experiments in
deriving distances between points of interest; therefore it is essential to obtain good
quality 1D spectra, which is facilitated by using as highly concentrated protein solutions
as is possible. Slightly reduced line widths are realized in the LS form of the protein,
which is obtained by removal of the bound camphor, however as shown in the trace II of
Figure 3.3.16, the spin state conversion from HS to LS is not 100%. This may be due to
incomplete removal of the substrate (camphor) following passage of the camphor bound
P450cam through Sephadex G25 column equilibrated with MOPS buffer. The optical
absorption spectra however showed the characteristic 417 nm band of the camphor-free
P450cam (SFP450cam). This was also observed for the 5-13C-ALA SFP450cam as shown
in Figure 3.3.16 (trace III); the percentage of the LS form of P450cam may be increased
by passing the protein through the column (equilibrated with MOPS buffer) a couple of
times before exchanging the buffer prior to collecting NMR data. In the 1D proton NMR
spectra the meso protons resonances are not easily identifiable even in the low spin form.
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They have been reported for P450cam to be possibly in the -20 and -40 ppm upfield
region.72 Fortunately, 13C enrichment at the four methine positions permits utilization of
13

C-filtered NMR methods, which can facilitate the identification of the meso protons.

However, the 2D NMR (HSQC) for the labeled SBP450cam (Figure 3.3.17 bottom trace),
indicates no major differences from the native SBP450cam spectrum and no detectable
meso resonances. The minor differences observed were later discovered to be due to the
formation of the inactive form of the enzyme (Figure 3.3.18). This is possibly due to the
long NMR acquisition times at room temperature, especially for the substrate free forms
of the enzyme, which gave similar results.
(b) Improved methods
The utilization of a strong ligand field ligand, such as cyanide, to induce LS
formation, is advantageous, noting that substrate-free LS forms, obtained by removing of
the camphor substrate, are unstable and will likely convert to the P420 form during long
NMR data collection. NMR studies on the cyanide complex of SBP450cam have been
reported previously.73 The low spin heme results in significantly reduced line widths,
which may augment NOE sensitivity. In addition, the stability of the cyanide complex of
SBP450cam permit for the acquisition of NMR data at elevated temperatures.72 In order
to improve the sensitivity of the NMR methods applied in this work, samples of the
cyanide complex of both the natural abundance and 13C enriched SBP450cam were
employed (vide infra).
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Figure 3.3.16 The 1D 1H NMR of the natural abundance SBP450cam (I), natural
abundance SFP450cam (II) and 5-13C-ALA SFP450cam (III); the heme methyl
resonances are denoted A-D

Figure 3.3.17 The 1D version of 1H-13C HSQC spectra of the natural abundance (top
trace) and 13C enriched (bottom trace) substrate-bound P450cam; sample concentration
was ~0.2 mM in 30 mM deuterated phosphate buffer
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Figure 3.3.18 The absorption spectrum of [5-13C] SBP450cam after collection of 1 D
1
H-13C HSQC data
Cyanoferricytochrome P450cam NMR
The NMR samples (natural abundance and 13C labeled) used in the experiments
described below contained ~ 0.4-1 mM P450cam in 30 mM phosphate D2O buffer, pH
7.4, 100 mM KCl, 10 mM KCN. The formation of the low spin substrate bound
cyanoferricytochrome P450cam was verified by absorption spectroscopy (Figure 3.3.19)
and is in agreement with the previously reported spectrum of the cyanide complex of
microsomal P450.146
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Figure 3.3.19 The absorption spectra high spin ferric substrate-bound P450cam (red
trace) and its cyanide complex (black trace)

3.3.4.1 1D 1H NMR
Proton NMR experiments were performed at 25 °C, for the cyanide complex of
the natural abundance and 13C-enriched substrate-bound P450cam, using a standard pulse
sequence (Figure 3.3.20). The hyperfine shifted signals occurring at 21.8 and 11.3 ppm
(black trace in Figure 3.3.20) have been assigned previously to the 8- and 3-methyl
peripheral groups, respectively.73 The 1D 1H spectrum of the 13C enriched cyanide
complex of SBP450cam (red trace) is essentially identical to the natural abundance (black
trace), as expected. However, due to the fast relaxation of protons in the paramagnetic
environment, the methine proton resonances are still not detectable, even at elevated
temperatures (40 °C), where only slight shifts are observed (blue trace). The 1D spectrum
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was collected before and after multidimensional experiments (vide infra) to ensure
sample integrity.

Figure 3.3.20 The 1D 1H NMR spectra of the natural abundance (black) and 13C enriched
cyanide complex of P450cam at 20 °C (red) and 40 °C (blue)

3.3.4.2 13C NMR
In order to determine the methine proton signals using a 2 D experiment
(HSQC/HMQC), a 1D 13C NMR was performed at 20 °C for both the natural abundance
and 13C enriched cyanide complex of SBP450cam (black and red traces in Figure 3.3.21).
The large line width arises from the very short relaxation time of the heme protons as
mentioned above. The carbon signals A-H (red trace), which are clearly absent from the
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natural abundance spectrum (black trace), were reasonably attributed to the 13C enriched
methine and Ccarbons of the heme consistent with the number of 13C labeled carbons
(red trace of Figure 3.3.21). Performing the experiment at 40 °C, for the 13C-enriched
SBP450cam, results in slight shifts to resonances A-E and attenuation of signals F, G and
H and appearance of a new (N) feature around 56 ppm (blue trace). This may be due to
the changes in longitudinal relaxation of the heme resonances at 40 °C.

Figure 3.3.21 The 13C NMR of the natural abundance (black trace) and 13C enriched (top
traces; red: 20 °C, blue: 40 °C) cyanide complex of P450cam. Insert shows the positions
of 13C enrichment (black dots)
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3.3.4.3 2D HMQC
Figure 3.3.22 shows the 2D HMQC spectra of the 13C enriched cyanide complex
of SBP450cam collected at 25 °C (red trace) and 40 °C (blue trace) with a recycle delay
of 10 ms and decoupling turned off. Protons giving rise to the signals labeled A-D are
reasonably assigned to the methine positions in as much as the corresponding 13C
chemical shifts (A-D) are consistent with those observed in the 1D 13C NMR experiment
for the labeled cyanide complex of SBP450cam (Figure 3.3.21). Interestingly, the
methine proton signals occur in the diamagnetic region making their identification
without selective 13C enrichment virtually impossible as noted in the 1D NMR
experiment above. This observation has been reported earlier in a similarly 13C enriched
heme cofactor of Hydrogenobacter thermophilus cytochrome c552.80 The four cross peaks
are clearly absent from the 2D HMQC spectrum of the natural abundance cyanide
complex of SBP450cam (Figure 3.3.23) further confirming their assignment to the 13C
enriched methine positions, however specific assignments (, ,  and ) is not possible
at this point. In the Hydrogenobacter thermophilus cytochrome c552, specific assignments
was achieved using 1H-1H NOESY cross-peaks between the heme methyl and meso
proton resonances.80 Without decoupling, one will expect to observe doublets in the
methine position cross peaks, however as noted above, the relatively fast relaxation, as
evident from the large line widths exhibited in the 13C NMR experiment, renders this
spectral resolution impossible. In addition, no 13C-13C coupling was observed in the 1D
13

C spectrum due to the inherent fast relaxation of these resonances. Also, noting that one

of the meso carbons ( position) is not attached to a 13C enriched pyrrole -carbon, one
would expect only 1H-13H coupling in contrast to the other 3 meso positions, which will
exhibit coupling from both the attached proton and labeled pyrrole -carbon. This
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unique, meso  carbon has been exploited in the assignment of the meso resonances by
NOE methods in similarly75,147 13C enriched heme oxygenases. However, probably due to
fast relaxation, these couplings were not observed in the current work. The 2D HMQC
spectra (obtained at 35 °C) of the cyanide complex of the heme oxygenase from
Coryne-bacterium diphtheria (cd-OH) that has been reconstituted with a heme group
13

C-labeled at the C and Cm positions exhibited four correlations at {58.58, -2.58},

{33.27, 2.42}, {21.73, 7.78} and {18.75, 8.19} assigned to meso-, ,  and  positions
respectively.147 In the current work a similar pattern was observed in the HMQC
experiment (Figure 3.3.22) performed at 40 °C with crosspeaks appearing {84.7, 2.1},
{77.6, 4.7}, {46.9, 8.3} and {40.6, 10.8}, however, with the resonances downshifted,
probably due to differences in the effect of the unpaired electron and active site
structures.
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Figure 3.3.22 The 2 D HMQC spectra for the 13C enriched cyanide complex of
SBP450cam collected at 25 °C (red) and 40 °C (blue).
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Figure 3.3.23 The 2D HMQC spectra of the natural abundance cyanide complex of
SBP450cam collected overnight at 25 °C
3.3.4.4 1H-1H NOESY
1

H-1H NOESY-HMQC data was collected with 100 ms pre-saturation delay and

10 ms mixing time. However, possibly due to low sensitivity, only two of the presumably
meso protons are detectable (Figure 3.3.24). The signal at 8.3 ppm exhibits 2 cross-peaks
at ~ 4.01 and 1.37 ppm, which are located in the proton resonances envelope. The
resonance at 4.01 ppm may be arising from the meso proton signal observed in the
HMQC spectra (red cross-peak B in Figure 3.3.22), however this signal shifts to 4.7 ppm
at 40 °C. Assignment of the signal at 1.37 ppm, is impossible at this point, since it may be
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arising either from the protein side chain residues or the substrate camphor. However,
detection of the corresponding signal at 1.37 ppm in the 1D 1H spectra of the 13Cenriched cyanide complex of SBP450cam is impossible due to the overwhelming protein
signals. The signal might be buried in the protein envelope, making it impossible to
detect, unless it was attached to a 13C-enriched carbon, where detection might be possible
using a double-filtered NOE. Interestingly, the 1H NMR spectrum of KPi buffer
containing free camphor exhibits a peak at 1.37 ppm arising from the 5 endo position of
the substrate camphor (Figure 3.3.25). According to the crystal structure of the cyanide
complex of P450cam, the 5 endo position is about 3.85 Å from the heme  position; thus,
the NOE at 1.37 ppm might possibly be arising from the 5 endo proton of camphor.
Assignment of this resonance can be confirmed by loss of NOE upon utilization of
perdueterated camphor or its substrate analogues, such as adamantanone. It is important
to note that the NOE sensitivity might be improved by optimizing the mixing time and
relaxation delay, this may lead to observation of additional crosspeaks, ideally from
substrate protons. This will possibly lead to the derivation of distances between the heme
reference points and substrate protons providing preliminary data on the disposition of
the substrate in the active site pocket.
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Figure 3.3.24 1H-1H NOSEY-HMQC spectrum of 13C-enriched cyanide complex of
SBP450cam at 40 °C
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Figure 3.3.25 1D 1H NMR of the 13C-enriched cyanide complex of SBP450cam at 40 °C,
with part of the diamagnetic region expanded (bottom trace) and KPi buffer containing
10 mM camphor (top trace)
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3.4 Summary
The specific aim of this work was to exploit NMR spectroscopy in deriving
experimental parameters for application in docking routines, which are commonly
employed in defining relative binding affinities in drug metabolism P450s. To this end,
an HU227 strain of E.coli, that lacks the -ALA synthase gene, was utilized in the
expression of P450cam harboring a prosthetic group labeled with 13C at the Cm and C
positions by supplementing the bacterial growth media with [5-13C] -ALA. The heme
precursor was successfully synthesized in four steps from [2-13C] glycine, giving yields
of up to 70%. Successful incorporation of 13C at the Cm and C positions was confirmed
by RR of the ferric form of SBP450cam. Significant perturbations of the oxidation and
spin state marker bands (in the high-frequency region) due to isotopic substitution were
observed. In the low-frequency RR, 7 downshifts with about 13 cm-1 upon isotopic
substitution. Additionally, activation of a vinyl bending mode at 412 cm-1 in the lowfrequency RR spectra of the 13C-enriched SBP450cam was observed, further confirming
successful expression of isotopically labeled P450cam.
In an effort to heterologously express a 13C-enriched CYP2D6, a truncated
CYP2D6 gene was designed and commercially synthesized. The gene delivered in a
pUC57 expression vector and transformed into E.coli cells, was shown to express P450
by reduced CO difference spectra of the total cell lysate. However, subcloning the gene
into the pCWori expression vector, which is normally used for P450 expression, did not
result in production of P450 as judged from the reduced CO difference spectra of total
cell lysate. In fact, a species chacteristic of a hexacoordinated heme was observed; this
was possibly due to the deletion in the pCWori sequence used for subcloning. Subcloning
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of the truncated gene of CYP2D6 into a functional pCWori+ expression vector might
possibly result in the production of functional soluble protein.
The 13C-enriched P450cam was employed in a ‘proof of principle’ exercise for the
strategy of defining active site structure in mammalian cytochromes P450 using NMR
methods to furnish necessary experimental restrictions in docking routines. Identification
of the meso protons was achieved by employing 1D 13C and HMQC experiments. The
HMQC spectra of cyanide complex of 13C-enriched SBP450cam exhibited four crosspeaks [{46.9, 8.3}, {40.6, 10.8}, {77.6, 4.7}, {84.7, 2.1}], the proton signals lie in the
diamagnetic region, making detection impossible without selective 13C-enrichment. 1H1

H-HMQC showed that, the signal at 8.3 ppm is within NOE distance to two resonances

at 1.37 and 4.01 ppm. However, assignment of these signals is impossible at this point, as
they are buried in the protein envelope, although the signal at 4.01 ppm might possibly be
coming from the heme meso proton, observed in the HMQC experiment performed at 25
°C. On the other hand the signal at 1.37 ppm corresponds to the 5 endo proton of
camphor, which is about 3.85 Å from the heme position, suggesting that the observed
NOE might be arising from the substrate. Utilization of perdeuterated camphor or its
substrate analogues (e.g. adamantanone) and concomitant loss of NOE to the 1.37 ppm
signal, will confirm its assignment to the 5 endo position. The sensitivity of the NOE
experiments could be improved by utilizing highly concentrated samples and exploiting
high field instruments such as the 900 MHz equipped with a cryoprobe. In addition,
expression of a fully deuterated proton will aid in the identification of NOEs only
between heme reference points and substrate or inhibitors. This will possibly lead to the
determination of relative distances between methine protons and substrate proton
resonances in the solution phase. It will be interesting to compare distances derived in the
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solution phase with those calculated from the corresponding crystal structure. Inasmuch
as there are still additional experiments to be done, the observation of NOEs from the
heme reference points in this ‘proof of principle’ exercise project, provides an
encouraging step in the direction of utilizing NMR methods in defining the active site
structure.
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